WO2014150748A2 - Stabilized single human cd4 domains and fusion proteins - Google Patents
Stabilized single human cd4 domains and fusion proteins Download PDFInfo
- Publication number
- WO2014150748A2 WO2014150748A2 PCT/US2014/024120 US2014024120W WO2014150748A2 WO 2014150748 A2 WO2014150748 A2 WO 2014150748A2 US 2014024120 W US2014024120 W US 2014024120W WO 2014150748 A2 WO2014150748 A2 WO 2014150748A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion protein
- hiv
- fusion
- seq
- polypeptide
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 154
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 154
- 241000282414 Homo sapiens Species 0.000 title description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 90
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 83
- 229920001184 polypeptide Polymers 0.000 claims abstract description 81
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 50
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 49
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 230000004927 fusion Effects 0.000 claims abstract description 31
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 44
- 239000013598 vector Substances 0.000 claims description 40
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 26
- 208000031886 HIV Infections Diseases 0.000 claims description 13
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 13
- 230000009385 viral infection Effects 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 208000037357 HIV infectious disease Diseases 0.000 claims description 8
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 8
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 8
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 8
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 239000002254 cytotoxic agent Substances 0.000 claims description 8
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 8
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102100021696 Syncytin-1 Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 description 88
- 230000027455 binding Effects 0.000 description 36
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 35
- 241000700605 Viruses Species 0.000 description 29
- -1 constructs Proteins 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 230000003612 virological effect Effects 0.000 description 19
- 241000124008 Mammalia Species 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000006386 neutralization reaction Methods 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000007910 cell fusion Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 102200093737 rs660339 Human genes 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000010415 tropism Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000002983 circular dichroism Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 108091006020 Fc-tagged proteins Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000000423 cell based assay Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001934 delay Effects 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 108010032976 Enfuvirtide Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229960002062 enfuvirtide Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960000884 nelfinavir Drugs 0.000 description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- XNTSZTNQFAPQDK-UHFFFAOYSA-N 2-methyl-3-(3-nitrophenyl)quinazolin-4-one;hydrochloride Chemical compound Cl.CC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC([N+]([O-])=O)=C1 XNTSZTNQFAPQDK-UHFFFAOYSA-N 0.000 description 1
- MQACHEJMUZIGJY-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-methylquinazolin-4-one;hydrochloride Chemical compound Cl.CC1=NC2=CC=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 MQACHEJMUZIGJY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100037437 Beta-defensin 1 Human genes 0.000 description 1
- 101710125314 Beta-defensin 1 Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101150080924 CNE1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101710143544 Griffithsin Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000560067 HIV-1 group M Species 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 101710100504 Heat shock protein beta-1 Proteins 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 description 1
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000780591 Homo sapiens AFG3-like protein 2 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000629361 Homo sapiens Paraplegin Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241001135958 Human type D retrovirus Species 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000007990 Organic Anion Transporters Human genes 0.000 description 1
- 108010089503 Organic Anion Transporters Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101710100842 Scytovirin Proteins 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010004408 TRPP Cation Channels Proteins 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 101150054895 ftsH gene Proteins 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 102000054037 human AFG3L2 Human genes 0.000 description 1
- 102000055335 human SPG7 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002859 polyalkenylene Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Definitions
- CD4 is a nonpolymophic transmembrane glycoprotein expressed on the surface of most thymocytes and a subpopulation of matured T cells (CD4 + T cells) (see Germain, Curr. Biol, 7: R640-R644 (1997)). It is composed of four immunoglobulin-like extracellular domains, a transmembrane segment and a cytoplasmic tail non-covalently associated with a src-family tyrosine kinase, Lck.
- CD4 functions as a co-receptor assisting the T cell receptor (TCR) on the CD4 + T cells for stronger association with class II major histocompatibility complex (MHCII) on antigen-presenting cells (APCs).
- TCR T cell receptor
- MHCII major histocompatibility complex
- APCs antigen-presenting cells
- CD4 also contributes directly to the signal transduction by driving signaling cascade through its kinase-linked cytoplasmic tail.
- the crystal structure of human CD4- murine MHCII shows that only the first extracellular domain (Dl) of CD4 makes contact with MHCII (see Wang et al., Proc. Natl Acad. Sci. USA, 98: 10799-10804 (2001)).
- CD4 is also the primary receptor for HIV-1 (see Dalgleish et al., Nature, 312: 763-767 (1984)). HIV-1 entry is initiated by binding of the viral envelope glycoprotein (Env) gpl20 to cellular receptor CD4. The interaction results in extensive conformational rearrangements of gpl20 and subsequently gp41 after engagement of a coreceptor (either CCR5 or CXCR4). The structural rearrangements of Envs and the interplay between Envs and the cellular receptor and co-receptor bring viral membrane toward target cell membrane, and eventually cause membrane fusion and viral entry.
- Env the viral envelope glycoprotein
- CD4 plays a key role in HIV-1 infection
- sCD4 solubly expressed CD4
- T4 all four
- D1D2 the first two extracellular domains
- Dl was generated by using a mutational strategy and purified from the sonication supernatant of E. coli.
- the purified protein was stable only at low pH (4.0) and partially improperly folded, and had affinity several-fold lower than that of D1D2 or T4.
- the invention provides a polypeptide comprising a single domain CD4, such as SEQ ID NO: 1 or SEQ ID NO: 2, as well as a fusion protein comprising the single domain CD4 and one or more fusion partners, wherein the one or more fusion partners optionally is joined to the single domain CD4 via a linker. Additionally, constructs comprising multivalent fusion proteins are provided. Nucleic acids encoding the single domain CD4 and fusion proteins, as well as compositions or cells comprising the single domain CD4, fusion proteins, constructs, or nucleic acids, also are provided. [0010] The invention also provides a method of inhibiting an HIV infection in a cell or a host comprising administering the polypeptide, fusion protein, or construct to the cell or host, such that the HIV infection is inhibited.
- Figure 1 is an amino acid sequence comparison between human single domain CD4 (Dl) and mutants thereof.
- Figure 2 is a depiction of constructs containing multiple fusion proteins, wherein A denotes an antibody or antibody fragment (e.g., m36.4), B denotes a single domain CD4 (e.g., the inventive polypeptide), C denotes a light chain constant region, D denotes a heavy chain constant region, and E denotes an Fc region or portion thereof. Straight lines connecting the regions denote linker sequences. The line represents optional bonds.
- A denotes an antibody or antibody fragment (e.g., m36.4)
- B denotes a single domain CD4 (e.g., the inventive polypeptide)
- C denotes a light chain constant region
- D denotes a heavy chain constant region
- E denotes an Fc region or portion thereof.
- Straight lines connecting the regions denote linker sequences. The line represents optional bonds.
- Figures 3 A and 3B are graphs depicting the binding of the Dl mutants with two different HIV- 1 envelope glycoproteins: gpl40c on -s (A) and gpl40c H i 2 . 05 44.2 (B).
- optical density at 450 nm is indicated on the y-axis and Dl mutant concentration (nM) is indicated on the x-axis.
- Figure 4 is a graph depicting the enhancing effects of the Dl mutants on binding of CD41 antibody m36hlFc to HIV-1 gpl40c on -s- Optical density at 450 nm is indicated on the y-axis and sCD4 concentration (nM) is indicated on the x-axis.
- Figures 5 A and 5B are graphs demonstrating that the Dl mutants consist primarily of ⁇ -strand secondary structures (A) and that mDl .22 has higher thermal stability than mDl .2 or mDl .23 (B).
- [O](103 deg cm dmol " ) is indicated on the y-axis and wavelength (nm) is indicated on the x-axis.
- the fraction folded (as assayed by circular dichroism) is indicated on the y-axis and temperature (°C) is indicated on the x-axis.
- Figure 6A is a graph demonstrating that the Dl mutants are monomeric (elute as one peak in size-exclusion chromatography).
- Figure 6B demonstrates that that mDl .22 does not tend to aggregate at high concentrations as shown by dynamic light scattering. Percent intensity at Day 0 or Day 7 at 4 °C or 37 °C is indicated on the y-axis and the size of mDl .22 (d.nm) is indicated on the x- axis.
- FIG. 7 demonstrates that an Fc-fusion protein of mDl .22 (mDl .22Fc) does not bind to MHC-expressing cells (human blood B (BJAB) and T (SUP-Tl) cell lines).
- MHC-expressing cells human blood B (BJAB) and T (SUP-Tl) cell lines.
- BJAB human blood B
- T SUP-Tl
- Figure 8A is a graph demonstrating that the A55V mutant of DlD2Fc (DlD2mFc) shows increased binding to HIV-1 gpl40c on -s as compared to DlD2Fc.
- FIG. 8B demonstrates that the A55 V mutant of D 1 D2Fc (D 1 D2mFc) has decreased interaction with human blood B and T cell lines (BJAB and SUP-T1) relative to
- Figure 9 is a graph demonstrating that the A55V mutation largely decreased binding of the CD4 Dl -specific antibody D9 to mD1.22Fc and DlD2mFc, which suggests that the mutation induces conformational changes in Dl .
- the optical density at 450 nm is indicated on the y-axis and the D9 concentration (nM) is indicated on the x-axis.
- Figure 10 is a graph demonstrating that mDl .22-36.4 fusion proteins (different valences) showed much lower binding to MHC-expressing cells (human blood B (BJAB) cell line) than D1D2FC
- Figures 1 1 A and 1 IB are graphs depicting that 4Dm2m and 6Dm2m do not enhance HIV-1 infectivity to two HIV-1 primary isolates (Bal in Fig. 1 1 A and JRFL in Fig. 1 IB) at low concentrations in contrast to D1D2.
- percent infectivity is indicated on the y-axis and concentration (nM) is indicated on the x-axis.
- IgGl ml02.4 is a control antibody specific to Nipah and Hendra viruses that did not inhibit any of the viruses.
- Figures 12A and 12B are graphs demonstrating the stability of 4Dm2m and 6Dm2m against degration in PBS and in human serum.
- concentration (nM) is indicated on the y-axis and incubation time (days) is indicated on the x-axis.
- CD4-Ig is used as a control.
- the invention provides a single domain CD4 that has the binding activity and specificity of full-length CD4 and maintains other functions, such as induction of
- the single domain CD4 Due to decreased molecular size, the single domain CD4 has excellent biological properties including improved binding kinetics, soluble expression in E. coli, higher solubility, stability and specificity, minimization of
- lymphoid environments e.g., spleen, lymph node and gut
- HIV-1 mostly replicates and spreads.
- the inventive single domain CD4 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
- the invention also provides a polypeptide comprising variants of SEQ ID NO: 1 or SEQ ID NO: 2 with up to 20 (e.g., 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, or 20) additions, deletions, substitutions, or insertions.
- the invention provides a polypeptide comprising SEQ ID NO: 1 or SEQ ID NO: 2 with up to 10 additions, deletions, substitutions, or insertions, wherein the polypeptide does not comprise SEQ ID NO: 4.
- the inventive polypeptide preferably is a recombinant or synthetic polypeptide, which is non-naturally occurring.
- the inventive polypeptide can be provided alone, or as part of a fusion protein comprising the polypeptide and one or more fusion partners.
- the fusion partner can be any suitable moiety that does not substantially inhibit the polypeptide's ability to bind its target. Desirably, the fusion partner enhances the stability and/or potency of the polypeptide as compared to the stability or potency of the polypeptide in the absence of the fusion partner.
- the fusion partner can be a naturally occurring protein or fragment thereof that resists degradation or removal by endogenous mechanisms in vivo, thereby increasing the half-life of the fusion protein as compared to the polypeptide in the absence of the fusion protein.
- suitable fusion partners include: (a) proteins from the extracellular matrix, such as collagen, laminin, integrin, and fibronectin; (b) proteins found in blood, such as serum albumin, serum albumin-binding peptide (SAbp), fibrinogen A, fibrinogen B, serum amyloid protein A, heptaglobin, protein, ubiquitin, uteroglobulin, ⁇ -2 microglobulin, plasminogen, lysozyme, cystatin C, a- 1 -antitrypsin, and pancreatic kypsin inhibitor; (c) immune serum proteins, such as IgE, IgG, IgM, and their fragments (e.g., Fc); (d) transport proteins, such as retinol binding protein; (e) defensins, such as ⁇ -defensin 1, neutrophil defensins 1, 2 and 3; (f) proteins found at the blood brain barrier or in neural tissues, such as
- the fusion partner is an immunoglobulin Fc region or portion thereof (e.g., the CH2 or CH3 region), especially the Fc region of a human immunoglobulin, such as a human IgGl Fc region.
- an Fc region or portion thereof for use in the invention include, but are not limited to, the amino acid sequence of SEQ ID NO: 7 and SEQ ID NO: 8.
- the fusion partner is an antibody or antibody fragment (e.g., Fab, scFv, dAb, etc.).
- the antibody is a single-domain antibody (a.k.a. "domain antibody (“dAb") or "engineered antibody domain” (“eAd”)), which is an antibody fragment consisting of a single monomeric variable antibody domain from the heavy or light chains.
- dAb domain antibody
- eAd engineered antibody domain
- the eAd can comprise SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16, also referenced herein as the m36, m36.1, m36.2, m36.4, or m36.5 antibodies, respectively.
- the fusion partner is an HIV (e.g., HIV-1 or HIV-2) envelope glycoprotein.
- HIV envelope glycoprotein examples include gpl20 and gpl40.
- the HIV envelope glycoprotein is HIV-1 gpl20.
- the fusion protein comprises one or more fusion partners (e.g., two, three, four, five, or more fusion partners).
- the fusion protein can comprise the inventive polypeptide, an eAd (e.g., the m36, m36.1, m36.2, m36.4, or m36.5 antibodies of SEQ ID NOs: 12-16, respectively) and a stability-enhancing fusion partner, such as an eAd (e.g., the m36, m36.1, m36.2, m36.4, or m36.5 antibodies of SEQ ID NOs: 12-16, respectively) and a stability-enhancing fusion partner, such as an HIV envelope glycoprotein.
- an eAd e.g., the m36, m
- immunoglobulin Fc region e.g., human IgGl Fc
- portion thereof e.g., CH3
- the inventive polypeptide and one or more fusion partners can be joined via a linker (i.e., a flexible molecular connection, such as a flexible polypeptide chain).
- the linker can be any suitable linker of any length, but is preferably at least about 15 (e.g., at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, or ranges thereof) amino acids in length.
- the linker is an amino acid sequence that is naturally present in immunoglobulin molecules of the host, such that the presence of the linker would not result in an immune response against the linker sequence by the mammal.
- linkers include, but are not limited to, linkers that comprise one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) G 4 S motifs, such as the linkers of SEQ ID NOs: 9-11.
- examples of fusion proteins according to the invention can have the following configuration: (first fusion partner)-(optional first linker)- (inventive polypeptide (referred to as mDl))-(optional second linker)-(optional second fusion partner). More specific illustrative examples include the following: mDl-Fc (SEQ ID NO: 17), gpl20-linker-mDl, eAd-linker-mDl, mDl-linker-CH3, eAd-linker-mDl-linker-CH3, and eAd-linker-mDl -Fc.
- the invention also provides a fusion protein comprising:
- A denotes an antibody or antibody fragment (e.g., Fab, scFv, eAd, etc.)
- B denotes the inventive polypeptide (SEQ ID NO: 1 or SEQ ID NO: 2; referred to as mDl)
- C denotes an immunoglobulin light chain constant region (e.g., human IgGl kappa light chain constant region)
- D denotes an immunoglobulin heavy chain constant region (e.g., human IgGl heavy chain constant region)
- E denotes an Fc region or a portion thereof (e.g., the Fc region from human IgGl).
- fusion proteins can be conjugated or otherwise joined in a larger construct.
- two fusion proteins of Formula (I) above and two fusion proteins of Formula (II) above can be assembled into a single construct, as depicted in Figure 2 (6Dm2m).
- the fusion protein of Formula (I) comprises SEQ ID NO: 23 and the fusion protein of Formula (II) comprises SEQ ID NO: 22.
- two fusion proteins of Formula (II) above and two fusion proteins of A-(optional linker)-C can be assembled into a single construct, as depicted in Figure 2 (4Dm2m).
- the fusion protein of Formula (III) comprises SEQ ID NO: 21 and the fusion protein of Formula (II) comprises SEQ ID NO: 20.
- two fusion proteins of Formula (III) above and two fusion proteins of B-(optional linker)-D-(optional linker)-E can be assembled into a single construct, as depicted in Figure 2 (2Dm2m).
- the fusion protein of Formula (III) can comprise SEQ ID NO: 19 and the fusion protein of Formula (IV) can comprise SEQ ID NO: 18.
- the individual fusion proteins can be joined in the manner typical of IgG type constructs, such as by disulfide bridges between the constant heavy and constant light regions and between the Fc regions.
- Two or more fusion proteins joined as a single construct desirably can provide a multivalent (bivalent, tetravalent, or even octavalent) molecule.
- constructs comprising two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) of the inventive fusion proteins also are encompassed by the invention.
- the fusion protein is assembled (e.g., self-assembled) to form one of the constructs depicted in Figure 2, wherein A denotes an antibody or antibody fragment (e.g., m36.4 eAd), B denotes the inventive polypeptide (e.g., mD1.22), C denotes an immunoglobulin light chain constant region (e.g., human IgGl kappa light chain constant region), D denotes an immunoglobulin heavy chain constant region (e.g., human IgGl heavy chain constant region), and E denotes an Fc region (e.g., the Fc region from human IgGl).
- A denotes an antibody or antibody fragment (e.g., m36.4 eAd)
- B denotes the inventive polypeptide (e.g., mD1.22)
- C denotes an immunoglobulin light chain constant region (e.g., human IgGl kappa light chain constant region)
- D denotes
- polypeptide and fusion protein can be PEGylated, or coupled to polymers of similar structure, function and purpose, to confer enhanced stability and half-life.
- PEGylation can provide increased half-life and resistance to degradation without a loss in activity (e.g., binding affinity) relative to non-PEGylated (e.g., antibody) polypeptides. Since PEGylation may not be advantageous with respect to some targets, in particular, those epitopes which are sterically-obstructed, the polypeptide or fusion protein should be minimally PEGylated so as not to negatively impact the accessibility to the size-restricted antigen.
- the polypeptide or fusion protein can be coupled to PEG or PEG-like polymers by any suitable means known in the art. Suitable PEG or PEG- like moieties can be synthetic or naturally occurring and include, but are not limited to, straight or branched chain
- polyalkylene polyalkenylene or polyoxyalkylene polymers, or a branched or unbranched polysaccharide, such as a homo- or heteropolysaccharide.
- synthetic polymers include straight or branched chain poly(ethylene glycol) (PEG), poly(propylene glycol), or poly( vinyl alcohol) and derivatives or substituted forms thereof.
- Substituted polymers for linkage to the domain antibodies also include substituted PEG, including methoxy(polyethylene glycol).
- Naturally occurring polymer moieties which can be used in addition to or in place of PEG include, for example, lactose, amylose, dextran, or glycogen, as well as derivatives thereof.
- the polypeptide or fusion protein can be multimerized, as for example, hetero- or homodimers, hetero- or homotrimers, hetero- or homotetramers, or higher order hetero- or homomultimers. Multimerization can increase the strength of antigen binding, wherein the strength of binding is related to the sum of the binding affinities of the multiple binding sites.
- cysteine residue(s) can be introduced in the amino acid sequence of the polypeptide or fusion proteins, thereby allowing interchain disulfide bond formation in a multimerized form.
- the homodimeric or heterodimeric (or multimeric) fusion proteins can include combinations of the same or different fusion partners (e.g., eAds), such that more than one epitope can be targeted at a time by the same construct.
- eAds fusion partners
- Such epitopes can be proximally located in the target (e.g., on the HIV target) such that the binding of one epitope facilitates the binding of the multimeric fusion proteins to the second or more epitopes.
- the epitopes targeted by multimeric fusion proteins also can be distally situated.
- Additional peptide sequences can be added to the fusion protein (or construct containing the fusion protein), which act to promote stability, purification, and/or detection.
- a reporter peptide portion e.g., green fluorescent protein (GFP), ⁇ - galactosidase, or a detectable domain thereof
- GFP green fluorescent protein
- Purification-facilitating peptide sequences include those derived or obtained from maltose binding protein (MBP), glutathione-S-transferase (GST), or thioredoxin (TRX).
- the polypeptide or fusion protein also or alternatively can be tagged with an epitope which can be antibody purified (e.g., the Flag epitope, which is commercially available from Kodak (New Haven, Connecticut)), a hexa-histidine peptide, such as the tag provided in a pQE vector available from QIAGEN, Inc. (Chatsworth, California), or an HA tag (as described in, e.g., Wilson et al., Cell, 37, 767 (1984)).
- an epitope which can be antibody purified (e.g., the Flag epitope, which is commercially available from Kodak (New Haven, Connecticut)), a hexa-histidine peptide, such as the tag provided in a pQE vector available from QIAGEN, Inc. (Chatsworth, California), or an HA tag (as described in, e.g., Wilson et al., Cell, 37, 767 (1984)).
- the polypeptide and fusion protein (or construct containing the fusion protein) can be prepared by any suitable method.
- the polypeptide and fusion protein can be prepared by synthesizing the amino acid sequence or by expressing a nucleic acid encoding the amino acid sequence in a cell and harvesting the resulting polypeptide or fusion protein from the cell. A combination of such methods also can be used. Methods of de novo synthesizing peptides and methods of recombinantly producing peptides are known in the art (see, e.g., Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press, Oxford, United Kingdom, 2005; Peptide and Protein Drug Analysis, ed.
- Conjugates comprising the polypeptide or fusion protein (or construct containing the fusion protein) of the invention conjugated to cytotoxic agents, such as chemotherapeutic agents, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof; a small molecule toxin), radioactive isotopes (i.e., a radioconjugate), or antiviral compounds (e.g., anti-HIV compounds) also are encompassed by the invention.
- cytotoxic agents such as chemotherapeutic agents, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof; a small molecule toxin), radioactive isotopes (i.e., a radioconjugate), or antiviral compounds (e.g., anti-HIV compounds) also are encompassed by the invention.
- cytotoxic agents such as chemotherapeutic
- the conjugates comprising cytotoxic agents can be used to target viral (e.g., HIV, such as HIV-1) infected cells and eradicate (destroy) such cells.
- viral e.g., HIV, such as HIV-1
- cytotoxic agents e.g., toxins
- the conjugate comprising (i) a cytotoxic agent and (ii) an antibody or antibody fragment containing construct as described herein
- the (ii) antibody or antibody fragment portion of the conjugate targets (detects) surface proteins of viral infected cells and (i) the cytotoxic agent portion of the conjugate eradicates (destroys) the targeted viral infected cells.
- the cells to be targeted are HIV (e.g., HIV-1) infected cells and the conjugate detects/targets the HIV (e.g., HIV-1) envelope glycoprotein expressed on the HIV infected cells.
- Administration of the conjugates can be used to destroy viral (e.g., HIV, such as HIV- 1) infected cells in a subject, thereby leading to successful treatment (cure) of the viral (e.g., HIV) infection in the subject.
- the invention provides a method for treating a viral infection in a subject comprising administering the inventive conjugate to the subject, thereby treating (curing) the viral infection in the subject by destroying the viral-infected cells in the subject.
- conjugates can be made using a variety of bifunctional protein coupling agents such as N- succinimidyl-3-(2-pyridyidithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p- diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene).
- SPDP N- succinimidyl-3-(2-pyridyidithiol)
- Detectable agents such as fluorescent compounds, also can be added to the polypeptide or fusion protein (or construct containing the fusion protein).
- exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5- dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin and the like.
- the polypeptide or fusion protein also can be derivatized with detectable enzymes, such as alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like.
- polypeptide or fusion protein construct When the polypeptide or fusion protein construct is derivatized with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a detectable reaction product.
- the polypeptide or fusion protein construct also can be derivatized with biotin, and detected through indirect measurement of avidin or streptavidin binding.
- the invention also provides a nucleic acid encoding the amino acid sequence of the polypeptide or fusion protein.
- the nucleic acid can comprise DNA or RNA, and can be single or double stranded.
- the nucleic acid can comprise nucleotide analogues or derivatives (e.g., inosine or phophorothioate nucleotides and the like).
- the nucleic acid can be provided as part of a construct comprising the nucleic acid and elements that enable delivery of the nucleic acid to a cell, and/or expression of the nucleic acid in a cell.
- elements include, for example, expression vectors, promoters, and transcription and/or translation sequences. Suitable vectors, promoters,
- the invention further provides a recombinant vector comprising the nucleic acid.
- suitable vectors include plasmids (e.g., DNA plasmids), yeast (e.g.,
- viral vectors such as poxvirus, retrovirus, adenovirus, adeno-associated virus, herpes virus, polio virus, alphavirus, baculorvirus, and Sindbis virus.
- the vector is a plasmid (e.g. DNA plasmid)
- the plasmid can be complexed with chitosan.
- the vector When the vector is for administration to a host (e.g., human), the vector preferably has a low replicative efficiency in a target cell (e.g., no more than about 1 progeny per cell or, more preferably, no more than 0.1 progeny per cell are produced). Replication efficiency can readily be determined empirically by determining the virus titer after infection of the target cell.
- a target cell e.g., no more than about 1 progeny per cell or, more preferably, no more than 0.1 progeny per cell are produced.
- Replication efficiency can readily be determined empirically by determining the virus titer after infection of the target cell.
- the polypeptide, fusion protein, conjugate, or construct can be administered to a mammal in the form of a cell comprising a nucleic acid encoding the polypeptide or fusion protein, optionally in the form of a vector.
- the invention also provides a cell comprising a vector or nucleic acid encoding the polypeptide or fusion protein from which the polypeptide or fusion protein desirably is secreted. Any suitable cell can be used.
- Examples include host cells, such as E. coli (e.g., E, coli Tb-1, TG-2, DH5a, XL-Blue MRF' (Stratagene), SA2821, and Y1090), Bacillus subtilis, Salmonella typhimurium, Serratia marcescens, Pseudomonas (e.g., P. aerugenosa), N. grassa, insect cells (e.g., Sf9, Ea4), yeast (S. cerevisiae) cells, and cells derived from a mammal, including human cell lines.
- E. coli e.g., E, coli Tb-1, TG-2, DH5a, XL-Blue MRF' (Stratagene), SA2821, and Y1090
- Bacillus subtilis e.g., E, coli Tb-1, TG-2, DH5a, XL-Blue MRF' (Stratagene), SA2821, and
- eukaryotic cells include VERO, HeLa, 3T3, Chinese hamster ovary (CHO) cells, W138 BHK, COS-7, and MDCK cells.
- a mammal such as a human
- the cell is a human B cell.
- Methods of introducing vectors into isolated host cells and the culture and selection of transformed host cells in vitro include the use of calcium chloride-mediated transformation, transduction, conjugation, triparental mating, DEAE, dextran-mediated transfection, infection, membrane fusion with liposomes, high velocity bombardment with DNA-coated microprojectiles, direct microinjection into single cells, and electroporation (see, e.g., Sambrook et al., supra, Davis et al., Basic Methods in Molecular Biology (1986), and Neumann et al., EMBO J. 1, 841 (1982)).
- the cell comprising the vector or nucleic acid expresses the nucleic acid encoding the polypeptide or fusion protein such that the nucleic acid sequence is transcribed and translated efficiently by the cell.
- the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell can be isolated.
- isolated encompasses compounds or compositions that have been removed from a biological environment (e.g., a cell, tissue, culture medium, body fluid, etc.) or otherwise increased in purity to any degree (e.g., isolated from a synthesis medium). Isolated compounds and compositions, thus, can be synthetic or naturally produced.
- the polypeptide, fusion protein, conjugate, nucleic acid, vector, or cell can be administered to any host (e.g., mammal, preferably a human) in need thereof.
- a host e.g., mammal, preferably a human
- viral infection e.g., HIV infection
- the inventive method can prophylactically or therapeutically inhibit infection by any type of HIV, but preferably inhibits HIV-1 and/or HIV-2 infection.
- the inventive method can be used to inhibit infection by any HIV group (e.g., groups M and/or O), and subtype (e.g., clades A, B,
- polypeptide, fusion protein, conjugate, nucleic acid, vector, or cell can be used to inhibit a broad range of viruses (see, e.g., Principles of Virology:
- viruses examples include, but are not limited to, Type C and Type D retroviruses, HTLV-1, HTLV-2, FIV, FLV, SIV, MLV, BLV, BIV, equine infectious virus, anemia virus, avian sarcoma viruses, such as Rous sarcoma virus (RSV), hepatitis type A, B, C, non-A and non-B viruses, arboviruses, varicella viruses, human herpes virus (e.g., HHV-6), measles, mumps, filovirus (e.g., Ebola, such as Ebola strains Sudan, Zaire, Cote d'lsian, and Reston), SARS, influenza, and rubella viruses.
- RSV Rous sarcoma virus
- hepatitis type A, B, C, non-A and non-B viruses arboviruses
- varicella viruses human herpes virus (e.g., HHV-6), meas
- the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof is provided at or after the diagnosis of viral (e.g., HIV) infection.
- viral e.g., HIV
- the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof is provided in advance of viral (e.g., HIV) infection, such as to patients or subjects who are at risk for being exposed to a virus (e.g., HIV) or who have been newly exposed to a virus (e.g., HIV).
- viruses e.g., HIV
- examples of such patients and subjects include, for example, healthcare workers, fetuses, neonates, or infants (e.g., nursing infants) whose mothers are infected or at risk for being infected, intravenous drug users, recipients of blood transfusions, blood products, or transplantation tissue, and other individuals who have been exposed to a body fluid that contains or may contain HIV.
- the prophylactic administration of the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof prevents, ameliorates, or delays viral (e.g., HIV) infection.
- a virus e.g., HIV
- efficacious treatment with the polypeptide, fusion protein, conjugate, nucleic acid, vector, cell, or composition thereof partially or completely inhibits or delays the appearance of the virus or minimizes the level of the virus in the blood or other body fluid of the exposed individual.
- polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof can be assessed in various ways well known to the skilled practitioner. For instance, one of ordinary skill in the art will understand that a polypeptide or fusion protein of the invention is efficacious in treating or inhibiting a viral (e.g., HIV) infection in a subject by observing that the polypeptide or fusion protein reduces viral load or delays or prevents a further increase in viral load.
- a viral e.g., HIV
- Viral loads can be measured by methods that are known in the art, for example, using PCR assays to detect the presence of viral (e.g., HIV) nucleic acid or antibody assays to detect the presence of viral (e.g., HIV) protein in a sample (e.g., blood or another body fluid) from a subject or patient, or by measuring the level of circulating anti-viral (e.g., anti-HIV) antibodies in the patient.
- Efficacy of the polypeptide or fusion protein treatment also can be determined by measuring the number of CD4+ T cells in the HIV-infected subject.
- a treatment that delays or inhibits an initial or further decrease in CD4+ T cells in an HIV-positive subject or patient, or that results in an increase in the number of CD4+ T cells in the HIV-positive subject can be considered efficacious.
- the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell can be formulated as a composition (e.g., pharmaceutical composition) comprising the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell and a carrier (e.g., a pharmaceutically or physiologically acceptable carrier).
- a composition e.g., pharmaceutical composition
- a carrier e.g., a pharmaceutically or physiologically acceptable carrier
- polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition of the invention can be used in the methods described herein alone or as part of a
- compositions comprising the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell can include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like.
- Suitable carriers and their formulations are described in A.R. Gennaro, ed., Remington: The Science and Practice of Pharmacy (19th ed.), Mack Publishing Company, Easton, PA (1995).
- Pharmaceutical carriers include sterile water, saline, Ringer's solution, dextrose solution, and buffered solutions at physiological pH.
- an appropriate amount of a pharmaceutically acceptable salt is used in the formulation to render the formulation isotonic.
- the pH of the formulation is preferably from about 5 to about 8 (e.g., about 5.5, about 6, about 6.5, about 7, about 7.5, and ranges thereof). More preferably, the pH is about 7 to about 7.5.
- Further carriers include sustained-release preparations, such as semipermeable matrices of solid hydrophobic polymers containing the fusion protein, which matrices are in the form of shaped articles (e.g., films, liposomes, or microparticles). It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.
- composition e.g., pharmaceutical composition
- composition can comprise more than one polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell of the invention.
- the composition can comprise one or more other
- pharmaceutically active agents or drugs examples include anticancer agents (e.g., chemotherapeutic drugs), antibiotics, antiviral drugs, antifungal drugs, cyclophosphamide, and combinations thereof.
- anticancer agents e.g., chemotherapeutic drugs
- antibiotics e.g., antibiotics, antiviral drugs, antifungal drugs, cyclophosphamide, and combinations thereof.
- Suitable antiviral agents include, but are not limited to, nucleoside/nucleotide reverse transcriptase inhibitors (e.g., lamivudine, abacavir, zidovudine, stavudine, didanosine, emtricitabine, and tenofovir), non-nucleoside reverse transcriptase inhibitors (e.g., delavirdine, efavirenz, etravirine, and nevirapine), protease inhibitors (e.g., amprenavir, fosamprenavir, atazanavir, darunavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, and tipranavir), fusion or entry inhibitors (e.g., enfuvirtide and maraviroc), integrase inhibitors (e.g., ralt
- Suitable methods of administering a polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof to hosts are known in the art.
- the host can be any suitable host, such as a mammal (e.g., a rodent, such as a mouse, rat, hamster, or guinea pig, rabbit, cat, dog, pig, goat, cow, horse, primate, or human).
- Administration can be topical (including ophthalmical, vaginal, rectal, intranasal, transdermal, and the like), oral, by inhalation, or parenteral (including by intravenous drip or subcutaneous, intracavity, intraperitoneal, or intramuscular injection).
- Topical intranasal administration refers to the delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid, vector, or fusion protein.
- Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation.
- Formulations for topical administration include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders.
- Conventional pharmaceutical carriers, aqueous, powder, or oily bases, thickeners, and the like may be necessary or desirable.
- compositions are to be administered parenterally, the administration is generally by injection.
- injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for suspension in liquid prior to injection, or as emulsions.
- parental administration can involve the preparation of a slow- release or sustained-release system, such that a constant dosage is maintained.
- Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives also can be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases, and the like.
- compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids, or binders may be desirable.
- compositions can potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids, such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base, such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases, such as mono-, di-, trialkyl, and aryl amines and substituted ethanolamines.
- inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid
- organic acids such as formic acid, acetic acid, propi
- polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell can be administered with a pharmaceutically acceptable carrier and can be delivered to the mammal's cells in vivo and/or ex vivo by a variety of mechanisms well-known in the art (e.g., uptake of naked DNA, liposome fusion, intramuscular injection of DNA via a gene gun, endocytosis, and the like).
- Viable host cells containing the nucleic acid or vector of the invention and expressing the fusion protein or conjugate can be used directly as the delivery vehicle for the fusion protein to the desired site(s) in vivo.
- Preferred host cells for the delivery of the fusion protein or conjugate directly to desired site(s), such as, for example, to a selected body cavity can comprise bacteria. More specifically, such host cells can comprise suitably engineered strain(s) of lactobacilli, enterococci, or other common bacteria, such as E. coli, normal strains of which are known to commonly populate body cavities.
- such host cells can comprise one or more selected nonpathogenic strains of lactobacilli, such as those described by Andreu et al., J. Infect. Dis., 171(5), 1237-43 (1995), especially those having high adherence properties to epithelial cells (e.g., vaginal epithelial cells) and suitably transformed using the nucleic acid or vector of the invention.
- lactobacilli such as those described by Andreu et al., J. Infect. Dis., 171(5), 1237-43 (1995)
- epithelial cells e.g., vaginal epithelial cells
- cells or tissues can be removed and maintained outside the body according to standard protocols known in the art.
- the compositions can be introduced into the cells via any gene transfer mechanism, such as calcium phosphate mediated gene delivery, electroporation, microinjection, or proteoliposomes.
- the transduced cells then can be infused (e.g., with a pharmaceutically acceptable carrier) or homotopically transplanted back into the mammal per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a mammal.
- compositions required to treat a viral infection will vary from mammal to mammal, depending on the species, age, gender, weight, and general condition of the mammal, the nature of the virus, the existence and extent of viral infection, the particular fusion proteins, nucleic acid, vector, or cell used, the route of administration, and whether other drugs are included in the regimen. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.
- Effective dosages and schedules for administering the nucleic acid molecules, vectors, cells, and fusion proteins of the invention can be determined empirically, and making such determinations is within the skill in the art.
- the dosage ranges for the administration of the compositions are those large enough to produce the desired effect; however, the dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Dosage can vary, and can be
- compositions administered in one or more (e.g., two or more, three or more, four or more, or five or more) doses daily, for one or more days.
- the composition can be administered before viral (e.g., HIV) infection or immediately upon determination of viral (e.g., HIV) infection and continuously administered until the virus is undetectable.
- viral e.g., HIV
- the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof is administered to a host (e.g., mammal, such as a human) in an amount effective to prophylactically or therapeutically inhibit an HIV infection.
- a host e.g., mammal, such as a human
- the efficacy of the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof as an HIV infection inhibitor may be determined by in vivo or in vitro parameters known in the art.
- any suitable dose of the polypeptide fusion protein, conjugate, nucleic acid, vector, cell, or composition thereof can be administered to a host.
- the appropriate dose will vary depending upon such factors as the host's age, weight, height, sex, general medical condition, previous medical history, and viral (e.g., HIV) infection progression and can be determined by a clinician.
- the polypeptide, fusion protein, or conjugate can be administered in a dose of about 1 ⁇ g/kg to up to 100 mg/kg of body weight or more per day (e.g., 5 ⁇ /13 ⁇ 4, 10 ⁇ /kg, 50 ⁇ gl g, 100 ⁇ xgl g, 200 xgl g, 300 ⁇ xgl g, 400 500 ⁇ ⁇ 1 ⁇ 2,
- Several doses e.g., 1 , 2, 3, 4, 5, 6, or more
- can be provided e.g., over a period of weeks or months).
- a suitable dose can include about 1 x 10 5 to about 1 x 10 12 (e.g., 1 x 10 6 , 1 x 10 7 , 1 x 10 8 , 1 x 10 9 , 1 x 10 10 , 1 x 10 11 , and ranges thereof) plaque forming units (pfus), although a lower or higher dose can be administered to a host.
- about 2 x 10 8 pfus can be administered (e.g., in a volume of about 0.5 niL).
- the inventive cells can be administered to a host in a dose of between about 1 x 10 5 and 2 x 10 11 (e.g., 1 x 10 6 , 1 x 10 7 , 1 x 10 8 , 1 x 10 9 , 1 x 10 10 , and ranges thereof) cells per infusion.
- the cells can be administered in, for example, one to three (e.g., two) infusions.
- the host can be administered a biological response modifier, such as interleukin 2 (IL-2).
- IL-2 interleukin 2
- the polypeptide or fusion protein (or construct containing the fusion protein) can be used in combination with other well-known viral (e.g., HIV) therapies and prophylactic vaccines already in use.
- the combination of the fusion protein of the invention can generate an additive or a synergistic effect with current treatments.
- the polypeptide or fusion protein (or construct containing the fusion protein) of the invention can be combined with other HIV and AIDS therapies and vaccines, such as highly active antiretroviral therapy (HAART), which comprises a combination of protease inhibitors and reverse transcriptase inhibitors, azidothymidine (AZT), structured treatment interruptions of HAART, cytokine immune enhancement therapy (e.g., interleukin (IL)-2, IL-12, CD40L + IL-12, IL-7, HIV protease inhibitors (e.g., ritonavir, indinavir, and nelfinavir, etc.), and interferons (IFNs)), cell replacement therapy, recombinant viral vector vaccines, DNA vaccines, inactivated virus preparations, immunosuppressive agents, such as Cyclosporin A, cyanovirin therapy (see, e.g., U.S.
- HAART highly active antiretroviral therapy
- IL interleukin
- Patent No. 6,015,876) scytovirin therapy (see, e.g., U.S. Patent No. 7,491,798), and griffithsin therapy (see, e.g., U.S. Patent Application Publication 2009-0092557).
- Such therapies can be administered in the manner already in use for the known treatment providing a therapeutic or prophylactic effect (see, e.g., Silvestri et al. Immune Intervention in AIDS. In: Immunology of Infectious Disease, H.E. Kauffman, A. Sher, and R. Ahmed eds., ASM Press, Washington DC (2002)).
- This example describes the identification of single domain CD4 (Dl) with improved soluble expression, stability, and specificity.
- Structure-guided cavity filling and library screening were used to identify Dl mutants with improved soluble expression, stability and specificity. The screening yielded two mutants: mD1.22 (SEQ ID NO: 1) and mD1.23 (SEQ ID NO: 2) (see Figure 1).
- the mutants were significantly more soluble in E. coli periplasm and PBS than the previously identified Dl mutant (mD1.2; Chen et al., J. Virol., 85: 9395-9405 (201 1)).
- ELISAs were performed with gpl40c on -s, which is a consensus gpl40 designed by aligning >1,000 sequences of group M (see Liao et al., Virology, 353: 268-282 (2006)), and gpl40cHi2.o 5 44.2- Bound mDl .2 and the mDl .22 and mDl .23 mutants were detected by HRP- conjugated anti-hexahistidine tag antibody (Sigma-Aldrich, St. Louis, MO).
- Binding of genetically diverse HIV-1 Envs also was analyzed by surface plama resonance (SPR) on a Biacore XI 00 appartus (GE Healthcare) using a single-cycle approach. Briefly, purified HIV-1 gpl40 was diluted in sodium acetate (pH 5.0) and immobilized directly onto a CM5 sensor chip via the standard amine coupling method. The reference cell was injected with N-hydroxysuccinimide-l-ethyl-3-(3-dimethyaminopropy)carbodiimide and ethanolamine without injection of gpl40.
- SPR surface plama resonance
- the Dl mutants and D1D2 were diluted with running buffer HSB-EP (100 mM HEPES (ph 7.4), 1.5 M NaCl, 30 mM EDTA, 0.5% surfactant 20). All analytes were tested at 500, 100, 20, 4, and 0.8 nM concentrations.
- CD4 induces conformational changes in gpl20 leading to exposure of CD4- inducible (CD4i) epitopes. To determine whether the Dl mutants induce such
- an CD4i antibody-based fusion protein m36hlFc (see Chen et al., Proc. Natl. Acad. Sci. USA, 105: 17121-17126 (2008)), was tested for binding to gpl40 Co n-s in the absence or presence of mDl .2 (SEQ ID NO: 3), mDl .22 (SEQ ID NO: 1), or mD1.23 (SEQ ID NO: 2).
- the two-domain human CD4 (D1D2; SEQ ID NO: 5) was used a positive control and Fab bl2, which is an HIV-1 broadly neutralizing antibody targeting the CD4- binding site on gpl20 (see Roben et al, J. Virol., 68: 4821-4828 (1994)), was used as the negative control.
- Binding of m36hlFc to gpl40co n -s was increased in the presence of the Dl mutants relative to the controls (see Fig. 4). Additionally, the binding m36hlFc to gpl40c on -s was increased or comparable to the binding observed in the presence of D1D2 and mDl .2, respectively (see Fig. 4).
- mD1.2 SEQ ID NO: 3
- mD1.22 SEQ ID NO: 1
- mD1.23 SEQ ID NO: 2
- the purified proteins were dissolved in PBS at the final concentration of 0.33 mg/niL, and the CD spectra were recorded on AVIV Model 202 CD Spectrometer (Aviv Biomedical). Wavelength spectra were recorded at 25 °C using a 0.1-cm path-length cuvette for native structure measurements. Thermal stability was measured at 216 nm by recording the CD signal in the temperature range of 25-90 °C with heating rate 1 °C/min.
- the temperature was recorded with an external probe sensor and the temperature inside the microcuvette was calculated by calibration; it was about 2-3 °C (range from 1.9 to 3.8 °C for temperatures from 20 to 80 °C) lower than the one measured by the external sensor. After heating, wavelength spectra were recorded at 90 °C.
- mDl .22 and mDl .23 consist primarily of ⁇ -strand secondary structures. mDl .22 has higher thermal stability than mDl .2 and mDl .23 (see Fig. 5B).
- mDl .22 and mDl .23 were uniformly monomeric in PBS at pH 7.4 as determined by size-exclusion chromatography. D1D2 also was monomeric but it was not eluted as a single peak (see Fig. 6 A). mDl .22 did not tend to aggregate at high concentrations (10 mg/niL) as shown by dynamic light scattering (see Fig. 6B).
- Fc-fusion proteins of D1D2, DlD2m (with A55V mutation; SEQ ID NO: 6), mDl .2, and mD1.22 were prepared using routine methods.
- mDl .22 SEQ ID NO: 1
- m36.4 SEQ ID NO: 15
- m36.4 is an engineered single human antibody domain targeting a CD4i epitope on HIV-1 gpl20.
- A corresponds to m36.4
- B corresponds to mDl .22
- C corresponds to a light chain constant region
- D corresponds to a heavy chain constant region
- E corresponds to an Fc region.
- 2Dm2m comprises two fusion proteins comprising SEQ ID NO: 18 and two fusion proteins comprising SEQ ID NO: 19.
- 4Dm2m comprises two fusion proteins comprising SEQ ID NO: 20 and two fusion proteins comprising SEQ ID NO: 21.
- 6Dm2m comprises two fusion proteins comprising SEQ ID NO: 22 and two fusion proteins comprising SEQ ID NO: 23.
- viruses pseudotyped with Envs from HIV-1 isolates representing clades A-E and using either CCR5 (R5) or CXCR4 (X4) or both (R5X4) as a coreceptor were included.
- Pseudoviruses were derived from 293T cells and a neutralization assay was performed in duplicate using HOS-CD4-CCR5 (for all R5 and dual tropic viruses) or HOS-CD4-CXCR4 cell lines as described in Chen et al., Proc. Natl. Acad. Sci. USA, 105: 17121-17126 (2008)).
- Luminescence was measured 48 hours post-infection and the percentage neutralization was calculated by the following formula: (1 - average RLU of inhibitor-containing wells/average RLU or virus-only wells) x 100. IC50 and ICgo of neutralization were assigned for the inhibitor concentration at which 50% and 90% neutralization were observed, respectively.
- mDl .22 and mDl .22-containing fusion proteins inhibited HIV-1 envelope glycoprotein-mediated cell fusion (see Tables 4 and 5). As shown in Table 5, 4Dm2m and 6Dm2m are more potent than VRCOl in inhibiting HIV-1 envelope glycoprotein mediated cell-cell fusion.
- T20 enfuvirtide
- CHR C-terminal heptad repeat
- C34 C-terminal heptad repeat
- CD4-Ig CD4-Ig for neutralizing activities against the panel
- the superior potencies of 4Dm2m and 6Dm2m also were observed when the IC90S were compared.
- This example deomonstrates thet solublility, stability, and aggregration propensity of the bispecific multivalent fusion proteins.
- JRFL B R5 18 ⁇ 5 10 6 ⁇ 4 2.9 ⁇ 0.4 25 ⁇ 1 1.2 ⁇ 0.1 25 ⁇ 6 0.090 ⁇ 0.008 0.59 ⁇ 0.06 0.060 ⁇ 0.014 0.29 ⁇ 0.09 0.043 ⁇ 0.004 0.21 ⁇ 0.01 a Antibody concentration (nM) resulting in 50% inhibition of virus infection.
- JRFL B R5 3.0 ⁇ 0.5 13 ⁇ 3 0.31 ⁇ 0.21 0.82 ⁇ 0.40 0.14 ⁇ 0.01 0.39 ⁇ 0.04 0.10 ⁇ 0.01 0.43 ⁇ 0.04
- JRCSF B 0.58 ⁇ 0.17 9.3 ⁇ 8.0 0.28 ⁇ 0.18 5.6 ⁇ 2.1 0.29 ⁇ 0.18 3.0 ⁇ 2.9 0.21 ⁇ 0.14 1.0 ⁇ 0.1
- Antibody concentration (nM) resulting in 50% inhibition of virus infection.
- Arithmetic and geometric means were calculated for all viruses including those with values ⁇ 0.021 nM, which were assigned a value of 0.01.
- the means for 2G12 were calculated based on the values with 10 isolates that were significantly neutralized.
- JRFL B R5 128 ⁇ 5 1075 ⁇ 35 66 ⁇ 1 208 ⁇ 4 66 ⁇ 1 >222 7.5 ⁇ 0.0 80 ⁇ 9 1.6 ⁇ 0.7 11 ⁇ 2 0.46 ⁇ 0.07 10 ⁇ 3 a Antibody concentration (nM) resulting in 50% inhibition of cell-cell fusion.
- the assay was performed in duplicate. Results are presented as mean without standard deviation. Means are calculated only when the difference between results for the duplicate assays was within 3 -fold.
- the bnAbs bl2 and VRCOl used in the neutralization assay are in IgGl format.
- Arithmetic and geometric means were calculated for all viruses including those with values >167 nM, which were assigned a value of 200, and those with values >250, which were assigned a value of 300.
- Geometric mean 6 11 3.5 42 1.7 0.22 0.20 123 25 195 17 3.5 2.4
- Arithmetic and geometric means were calculated for all viruses including those with values >750 nM, which were assigned a value of 800, those with values >250 nM, which were assigned a value of 300, those with values >100, which were assigned a value of 150, and those with values >28 nM, which were assigned a value of 30.
- mDl .22 has improved soluble expression and stability, showed no measurable interaction with human blood B and T cell lines, and preserved binding and cross-reactivity with HIV-1 gpl20.
- mD1.22-m36.4 fusion proteins have been shown to be potent HIV-1 neutralizers and multivalent mD1.22-m36.4 fusion proteins do not tend to enhance HIV-1 infectivity.
- the newly identified mutants can be used for HIV-1 prevention and therapy, and also can serve as valuable tools to study the mechanism of HIV-1 entry and biological functions of CD4 in immune responses.
Abstract
The invention provides a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the single domain CD4 and one or more fusion partners. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.
Description
STABILIZED SINGLE HUMAN CD4 DOMAINS AND FUSION PROTEINS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application claims the benefit of U.S. Provisional Patent Application No. 61/791,885, filed on March 15, 2013, which is incorporated by reference.
SEQUENCE LISTING
[0002] Incorporated by reference in its entirety herein is a nucleotide/amino acid sequence listing submitted concurrently herewith.
BACKGROUND OF THE INVENTION
[0003] CD4 is a nonpolymophic transmembrane glycoprotein expressed on the surface of most thymocytes and a subpopulation of matured T cells (CD4+ T cells) (see Germain, Curr. Biol, 7: R640-R644 (1997)). It is composed of four immunoglobulin-like extracellular domains, a transmembrane segment and a cytoplasmic tail non-covalently associated with a src-family tyrosine kinase, Lck. As an important component of the immune system, CD4 functions as a co-receptor assisting the T cell receptor (TCR) on the CD4+ T cells for stronger association with class II major histocompatibility complex (MHCII) on antigen-presenting cells (APCs). The association is sufficient to trigger T-cell signaling transduction resulting in activation of the CD4+ T cells.
[0004] CD4 also contributes directly to the signal transduction by driving signaling cascade through its kinase-linked cytoplasmic tail. The crystal structure of human CD4- murine MHCII shows that only the first extracellular domain (Dl) of CD4 makes contact with MHCII (see Wang et al., Proc. Natl Acad. Sci. USA, 98: 10799-10804 (2001)).
However, mutational analysis indicates that in addition to Dl, other domains also affect binding to MHCII (see Moebius et al., Proc. Natl. Acad. Sci. USA, 90: 8259-8263 (1993)). Moreover, oligomerization of CD4 is required for stable interaction with MHCII and efficient T-cell activation (see Sakihama et al., Proc. Natl. Acad. Sci. USA, 92: 6444-6448 (1995)).
[0005] CD4 is also the primary receptor for HIV-1 (see Dalgleish et al., Nature, 312: 763-767 (1984)). HIV-1 entry is initiated by binding of the viral envelope glycoprotein (Env) gpl20 to cellular receptor CD4. The interaction results in extensive conformational rearrangements of gpl20 and subsequently gp41 after engagement of a coreceptor (either
CCR5 or CXCR4). The structural rearrangements of Envs and the interplay between Envs and the cellular receptor and co-receptor bring viral membrane toward target cell membrane, and eventually cause membrane fusion and viral entry. Because CD4 plays a key role in HIV-1 infection, recombinant solubly expressed CD4 (sCD4) containing either all four (T4) (see Deen et al., Nature, 331: 82-84 (1988)) or the first two extracellular domains (D1D2) (see Traunecker et al., Nature, 331: 84-86 (1988)) is a potent inhibitor of HIV-1 entry and used for crystallization alone (see Wu et al., Nature, 387: 527-530 (1997) and Ryu et al., Nature, 348: 419-429 (1990)) or with gpl20 (see Kwong et al., Nature, 393: 648-659 (1998)).
[0006] In Sharma et al. {Biochemistry, 44: 16192-16202 (2005)), Dl was generated by using a mutational strategy and purified from the sonication supernatant of E. coli. However, the purified protein was stable only at low pH (4.0) and partially improperly folded, and had affinity several-fold lower than that of D1D2 or T4.
[0007] In Chen et al. (J Virol , 85: 9395-9405 (2011)), two stable monomeric Dl mutants, mDl . l and mD1.2 were identified, which were significantly more soluble and bound Env gpl20s more strongly (50-fold) than D1D2, neutralized a panel of HIV-1 primary isolates from different clades more potently than D1D2, induced conformation changes in gpl20, and sensitized HIV-1 for neutralization by CD4-induced antibodies.
[0008] However, the desire for new Dls that are correctly folded, highly soluble and stable under physiological conditions while preserving not only binding activity and specificity but also other functions, such as induction of conformational changes in HIV-1 gpl20, remains.
BRIEF SUMMARY OF THE INVENTION
[0009] The invention provides a polypeptide comprising a single domain CD4, such as SEQ ID NO: 1 or SEQ ID NO: 2, as well as a fusion protein comprising the single domain CD4 and one or more fusion partners, wherein the one or more fusion partners optionally is joined to the single domain CD4 via a linker. Additionally, constructs comprising multivalent fusion proteins are provided. Nucleic acids encoding the single domain CD4 and fusion proteins, as well as compositions or cells comprising the single domain CD4, fusion proteins, constructs, or nucleic acids, also are provided.
[0010] The invention also provides a method of inhibiting an HIV infection in a cell or a host comprising administering the polypeptide, fusion protein, or construct to the cell or host, such that the HIV infection is inhibited.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[0011] Figure 1 is an amino acid sequence comparison between human single domain CD4 (Dl) and mutants thereof.
[0012] Figure 2 is a depiction of constructs containing multiple fusion proteins, wherein A denotes an antibody or antibody fragment (e.g., m36.4), B denotes a single domain CD4 (e.g., the inventive polypeptide), C denotes a light chain constant region, D denotes a heavy chain constant region, and E denotes an Fc region or portion thereof. Straight lines connecting the regions denote linker sequences. The line represents optional bonds.
[0013] Figures 3 A and 3B are graphs depicting the binding of the Dl mutants with two different HIV- 1 envelope glycoproteins: gpl40con-s (A) and gpl40cHi2.0544.2 (B). In each of the graphs, optical density at 450 nm is indicated on the y-axis and Dl mutant concentration (nM) is indicated on the x-axis.
[0014] Figure 4 is a graph depicting the enhancing effects of the Dl mutants on binding of CD41 antibody m36hlFc to HIV-1 gpl40con-s- Optical density at 450 nm is indicated on the y-axis and sCD4 concentration (nM) is indicated on the x-axis.
[0015] Figures 5 A and 5B are graphs demonstrating that the Dl mutants consist primarily of β-strand secondary structures (A) and that mDl .22 has higher thermal stability than mDl .2 or mDl .23 (B). In Figure 5A, [O](103 deg cm dmol" ) is indicated on the y-axis and wavelength (nm) is indicated on the x-axis. In Figure 5B, the fraction folded (as assayed by circular dichroism) is indicated on the y-axis and temperature (°C) is indicated on the x-axis.
[0016] Figure 6A is a graph demonstrating that the Dl mutants are monomeric (elute as one peak in size-exclusion chromatography).
[0017] Figure 6B demonstrates that that mDl .22 does not tend to aggregate at high concentrations as shown by dynamic light scattering. Percent intensity at Day 0 or Day 7 at 4 °C or 37 °C is indicated on the y-axis and the size of mDl .22 (d.nm) is indicated on the x- axis.
[0018] Figure 7 demonstrates that an Fc-fusion protein of mDl .22 (mDl .22Fc) does not bind to MHC-expressing cells (human blood B (BJAB) and T (SUP-Tl) cell lines). The dark
curve contains reference cells only, while the light curve contains cells and Fc-fusion proteins.
[0019] Figure 8A is a graph demonstrating that the A55V mutant of DlD2Fc (DlD2mFc) shows increased binding to HIV-1 gpl40con-s as compared to DlD2Fc.
[0020] Figure 8B demonstrates that the A55 V mutant of D 1 D2Fc (D 1 D2mFc) has decreased interaction with human blood B and T cell lines (BJAB and SUP-T1) relative to
D1D2FC.
[0021] Figure 9 is a graph demonstrating that the A55V mutation largely decreased binding of the CD4 Dl -specific antibody D9 to mD1.22Fc and DlD2mFc, which suggests that the mutation induces conformational changes in Dl . The optical density at 450 nm is indicated on the y-axis and the D9 concentration (nM) is indicated on the x-axis.
[0022] Figure 10 is a graph demonstrating that mDl .22-36.4 fusion proteins (different valences) showed much lower binding to MHC-expressing cells (human blood B (BJAB) cell line) than D1D2FC
[0023] Figures 1 1 A and 1 IB are graphs depicting that 4Dm2m and 6Dm2m do not enhance HIV-1 infectivity to two HIV-1 primary isolates (Bal in Fig. 1 1 A and JRFL in Fig. 1 IB) at low concentrations in contrast to D1D2. In each graph, percent infectivity is indicated on the y-axis and concentration (nM) is indicated on the x-axis. IgGl ml02.4 (see Zhu et al., J. Infect. Dis., 197: 846-853 (2008)), is a control antibody specific to Nipah and Hendra viruses that did not inhibit any of the viruses.
[0024] Figures 12A and 12B are graphs demonstrating the stability of 4Dm2m and 6Dm2m against degration in PBS and in human serum. In each graph, concentration (nM) is indicated on the y-axis and incubation time (days) is indicated on the x-axis. CD4-Ig is used as a control.
DETAILED DESCRIPTION OF THE INVENTION
[0025] The invention provides a single domain CD4 that has the binding activity and specificity of full-length CD4 and maintains other functions, such as induction of
conformational changes in HIV-1 gpl20. Due to decreased molecular size, the single domain CD4 has excellent biological properties including improved binding kinetics, soluble expression in E. coli, higher solubility, stability and specificity, minimization of
immunogenicity in animals, and better penetration into tissues, such as the densely packed
lymphoid environments (e.g., spleen, lymph node and gut) where HIV-1 mostly replicates and spreads.
[0026] The inventive single domain CD4 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The invention also provides a polypeptide comprising variants of SEQ ID NO: 1 or SEQ ID NO: 2 with up to 20 (e.g., 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, or 20) additions, deletions, substitutions, or insertions. Preferably, the invention provides a polypeptide comprising SEQ ID NO: 1 or SEQ ID NO: 2 with up to 10 additions, deletions, substitutions, or insertions, wherein the polypeptide does not comprise SEQ ID NO: 4.
[0027] The inventive polypeptide preferably is a recombinant or synthetic polypeptide, which is non-naturally occurring.
[0028] The inventive polypeptide can be provided alone, or as part of a fusion protein comprising the polypeptide and one or more fusion partners. The fusion partner can be any suitable moiety that does not substantially inhibit the polypeptide's ability to bind its target. Desirably, the fusion partner enhances the stability and/or potency of the polypeptide as compared to the stability or potency of the polypeptide in the absence of the fusion partner. For instance, the fusion partner can be a naturally occurring protein or fragment thereof that resists degradation or removal by endogenous mechanisms in vivo, thereby increasing the half-life of the fusion protein as compared to the polypeptide in the absence of the fusion protein.
[0029] Examples of suitable fusion partners include: (a) proteins from the extracellular matrix, such as collagen, laminin, integrin, and fibronectin; (b) proteins found in blood, such as serum albumin, serum albumin-binding peptide (SAbp), fibrinogen A, fibrinogen B, serum amyloid protein A, heptaglobin, protein, ubiquitin, uteroglobulin, β-2 microglobulin, plasminogen, lysozyme, cystatin C, a- 1 -antitrypsin, and pancreatic kypsin inhibitor; (c) immune serum proteins, such as IgE, IgG, IgM, and their fragments (e.g., Fc); (d) transport proteins, such as retinol binding protein; (e) defensins, such as β-defensin 1, neutrophil defensins 1, 2 and 3; (f) proteins found at the blood brain barrier or in neural tissues, such as melanocortin receptor, myelin, ascorbate transporter; (g) transferrin receptor specific ligand- neuropharmaceutical agent fusion proteins, brain capillary endothelial cell receptor, transferrin, transferrin receptor, insulin, insulin-like growth factor 1 (IGF 1) receptor, insulinlike growth factor 2 (IGF 2) receptor, insulin receptor; (h) proteins localized to the kidney, such as polycystin, type IV collagen, organic anion transporter Kl, Heymann's antigen; (i)
proteins localized to the liver, such as alcohol dehydrogenase, G250; (j) blood coagulation factor X; (k) a-1 antitrypsin; (1) HNF 1 a; (m) proteins localized to the lung, such as secretory component; (n) proteins localized to the heart, such as HSP 27; (o) proteins localized to the skin, such as keratin; (p) bone specific proteins, such as bone morphogenic proteins (BMPs), for example, BMP-2, -4, -5, -6, -7 (also referred to as osteogenic protein (OP-I) and -8 (OP-2); (q) tumor specific proteins, such as human trophoblast antigen, herceptin receptor, estrogen receptor, cathepsins, for example, cathepsin B (found in liver and spleen); (r) disease-specific proteins, such as antigens expressed only on activated T-cells: including LAG-3 (lymphocyte activation gene); osteoprotegerin ligand (OPGL); OX40; metalloproteases, including CG6512 Drosophila, human paraplegin, human FtsH, human AFG3L2, murine ftsH; angiogenic growth factors, including acidic fibroblast growth factor (FGF-I), basic fibroblast growth factor (FGF-2), Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), transforming growth factor-a (TGF-a), tumor necrosis factor-alpha (TNF-a), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet derived endothelial growth factor (PD-ECGF), placental growth factor (PIGF), midkine platelet- derived growth factor-BB (PDGF), fractalkine; (s) stress proteins (heat shock proteins); and (t) proteins involved in Fc transport. Additional fusion partners for use in connection herewith are described in WO 2009/089295.
[0030] In one embodiment, the fusion partner is an immunoglobulin Fc region or portion thereof (e.g., the CH2 or CH3 region), especially the Fc region of a human immunoglobulin, such as a human IgGl Fc region. Examples of an Fc region or portion thereof for use in the invention include, but are not limited to, the amino acid sequence of SEQ ID NO: 7 and SEQ ID NO: 8.
[0031] In another embodiment, the fusion partner is an antibody or antibody fragment (e.g., Fab, scFv, dAb, etc.). Preferably, the antibody is a single-domain antibody (a.k.a. "domain antibody ("dAb") or "engineered antibody domain" ("eAd")), which is an antibody fragment consisting of a single monomeric variable antibody domain from the heavy or light chains. For example, the eAd can comprise SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16, also referenced herein as the m36, m36.1, m36.2, m36.4, or m36.5 antibodies, respectively.
[0032] In another embodiment, the fusion partner is an HIV (e.g., HIV-1 or HIV-2) envelope glycoprotein. Examples of the HIV envelope glycoprotein include gpl20 and gpl40. Preferably, the HIV envelope glycoprotein is HIV-1 gpl20.
[0033] The fusion protein comprises one or more fusion partners (e.g., two, three, four, five, or more fusion partners). For instance, the fusion protein can comprise the inventive polypeptide, an eAd (e.g., the m36, m36.1, m36.2, m36.4, or m36.5 antibodies of SEQ ID NOs: 12-16, respectively) and a stability-enhancing fusion partner, such as an
immunoglobulin Fc region (e.g., human IgGl Fc) or portion thereof (e.g., CH3).
[0034] The inventive polypeptide and one or more fusion partners can be joined via a linker (i.e., a flexible molecular connection, such as a flexible polypeptide chain). The linker can be any suitable linker of any length, but is preferably at least about 15 (e.g., at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, or ranges thereof) amino acids in length. In one embodiment, the linker is an amino acid sequence that is naturally present in immunoglobulin molecules of the host, such that the presence of the linker would not result in an immune response against the linker sequence by the mammal. Examples of suitable linkers include, but are not limited to, linkers that comprise one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) G4S motifs, such as the linkers of SEQ ID NOs: 9-11.
[0035] By way of further illustration, examples of fusion proteins according to the invention can have the following configuration: (first fusion partner)-(optional first linker)- (inventive polypeptide (referred to as mDl))-(optional second linker)-(optional second fusion partner). More specific illustrative examples include the following: mDl-Fc (SEQ ID NO: 17), gpl20-linker-mDl, eAd-linker-mDl, mDl-linker-CH3, eAd-linker-mDl-linker-CH3, and eAd-linker-mDl -Fc.
[0036] The invention also provides a fusion protein comprising:
A-(optional linker)-C-(optional linker)-B (Formula (I))
or
B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula (II)) wherein A denotes an antibody or antibody fragment (e.g., Fab, scFv, eAd, etc.), B denotes the inventive polypeptide (SEQ ID NO: 1 or SEQ ID NO: 2; referred to as mDl), C denotes an immunoglobulin light chain constant region (e.g., human IgGl kappa light chain constant region), D denotes an immunoglobulin heavy chain constant region (e.g., human IgGl heavy chain constant region), and E denotes an Fc region or a portion thereof (e.g., the Fc region from human IgGl). Specific examples include mD1.22-linker-human IgGl heavy chain constant region-linker-mDl and 36.4 eAd-linker-human IgGl light chain constant region- linker-mDl .22.
[0037] Two or more of the fusion proteins can be conjugated or otherwise joined in a larger construct. For instance, two fusion proteins of Formula (I) above and two fusion proteins of Formula (II) above can be assembled into a single construct, as depicted in Figure 2 (6Dm2m). In one embodiment, the fusion protein of Formula (I) comprises SEQ ID NO: 23 and the fusion protein of Formula (II) comprises SEQ ID NO: 22.
[0038] Alternatively, two fusion proteins of Formula (II) above and two fusion proteins of A-(optional linker)-C (Formula III) can be assembled into a single construct, as depicted in Figure 2 (4Dm2m). In one embodiment, the fusion protein of Formula (III) comprises SEQ ID NO: 21 and the fusion protein of Formula (II) comprises SEQ ID NO: 20.
[0039] In another embodiment, two fusion proteins of Formula (III) above and two fusion proteins of B-(optional linker)-D-(optional linker)-E (Formula IV) can be assembled into a single construct, as depicted in Figure 2 (2Dm2m). The fusion protein of Formula (III) can comprise SEQ ID NO: 19 and the fusion protein of Formula (IV) can comprise SEQ ID NO: 18.
[0040] The individual fusion proteins can be joined in the manner typical of IgG type constructs, such as by disulfide bridges between the constant heavy and constant light regions and between the Fc regions. Two or more fusion proteins joined as a single construct desirably can provide a multivalent (bivalent, tetravalent, or even octavalent) molecule.
[0041] Thus, constructs comprising two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) of the inventive fusion proteins also are encompassed by the invention.
[0042] In one embodiment, the fusion protein is assembled (e.g., self-assembled) to form one of the constructs depicted in Figure 2, wherein A denotes an antibody or antibody fragment (e.g., m36.4 eAd), B denotes the inventive polypeptide (e.g., mD1.22), C denotes an immunoglobulin light chain constant region (e.g., human IgGl kappa light chain constant region), D denotes an immunoglobulin heavy chain constant region (e.g., human IgGl heavy chain constant region), and E denotes an Fc region (e.g., the Fc region from human IgGl).
[0043] The polypeptide and fusion protein can be PEGylated, or coupled to polymers of similar structure, function and purpose, to confer enhanced stability and half-life.
PEGylation can provide increased half-life and resistance to degradation without a loss in activity (e.g., binding affinity) relative to non-PEGylated (e.g., antibody) polypeptides. Since PEGylation may not be advantageous with respect to some targets, in particular, those epitopes which are sterically-obstructed, the polypeptide or fusion protein should be
minimally PEGylated so as not to negatively impact the accessibility to the size-restricted antigen. The polypeptide or fusion protein can be coupled to PEG or PEG-like polymers by any suitable means known in the art. Suitable PEG or PEG- like moieties can be synthetic or naturally occurring and include, but are not limited to, straight or branched chain
polyalkylene, polyalkenylene or polyoxyalkylene polymers, or a branched or unbranched polysaccharide, such as a homo- or heteropolysaccharide. Preferred examples of synthetic polymers include straight or branched chain poly(ethylene glycol) (PEG), poly(propylene glycol), or poly( vinyl alcohol) and derivatives or substituted forms thereof. Substituted polymers for linkage to the domain antibodies also include substituted PEG, including methoxy(polyethylene glycol). Naturally occurring polymer moieties which can be used in addition to or in place of PEG include, for example, lactose, amylose, dextran, or glycogen, as well as derivatives thereof.
[0044] The polypeptide or fusion protein can be multimerized, as for example, hetero- or homodimers, hetero- or homotrimers, hetero- or homotetramers, or higher order hetero- or homomultimers. Multimerization can increase the strength of antigen binding, wherein the strength of binding is related to the sum of the binding affinities of the multiple binding sites. In particular, cysteine residue(s) can be introduced in the amino acid sequence of the polypeptide or fusion proteins, thereby allowing interchain disulfide bond formation in a multimerized form. The homodimeric or heterodimeric (or multimeric) fusion proteins can include combinations of the same or different fusion partners (e.g., eAds), such that more than one epitope can be targeted at a time by the same construct. Such epitopes can be proximally located in the target (e.g., on the HIV target) such that the binding of one epitope facilitates the binding of the multimeric fusion proteins to the second or more epitopes. The epitopes targeted by multimeric fusion proteins also can be distally situated.
[0045] Additional peptide sequences can be added to the fusion protein (or construct containing the fusion protein), which act to promote stability, purification, and/or detection. For example, a reporter peptide portion (e.g., green fluorescent protein (GFP), β- galactosidase, or a detectable domain thereof) can be used. Purification-facilitating peptide sequences include those derived or obtained from maltose binding protein (MBP), glutathione-S-transferase (GST), or thioredoxin (TRX). The polypeptide or fusion protein (or construct containing the fusion protein) also or alternatively can be tagged with an epitope which can be antibody purified (e.g., the Flag epitope, which is commercially available from Kodak (New Haven, Connecticut)), a hexa-histidine peptide, such as the tag provided in a
pQE vector available from QIAGEN, Inc. (Chatsworth, California), or an HA tag (as described in, e.g., Wilson et al., Cell, 37, 767 (1984)).
[0046] The polypeptide and fusion protein (or construct containing the fusion protein) can be prepared by any suitable method. For example, the polypeptide and fusion protein can be prepared by synthesizing the amino acid sequence or by expressing a nucleic acid encoding the amino acid sequence in a cell and harvesting the resulting polypeptide or fusion protein from the cell. A combination of such methods also can be used. Methods of de novo synthesizing peptides and methods of recombinantly producing peptides are known in the art (see, e.g., Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press, Oxford, United Kingdom, 2005; Peptide and Protein Drug Analysis, ed. Reid, R., Marcel Dekker, Inc., 2000; Epitope Mapping, ed. Westwood et al., Oxford University Press, Oxford, United Kingdom, 2000; Sambrook et al., Molecular Cloning: A Laboratory Manual, 3 ed., Cold Spring Harbor Press, Cold Spring Harbor, NY 2001 ; and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, NY, 1994).
[0047] Conjugates comprising the polypeptide or fusion protein (or construct containing the fusion protein) of the invention conjugated to cytotoxic agents, such as chemotherapeutic agents, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof; a small molecule toxin), radioactive isotopes (i.e., a radioconjugate), or antiviral compounds (e.g., anti-HIV compounds) also are encompassed by the invention. Alternatively, the polypeptide or fusion protein (or construct containing the fusion protein) can be co-administered with the cytotoxic agents, antiviral compounds, and the like.
[0048] The conjugates comprising cytotoxic agents (e.g., toxins) can be used to target viral (e.g., HIV, such as HIV-1) infected cells and eradicate (destroy) such cells. For example, with a conjugate comprising (i) a cytotoxic agent and (ii) an antibody or antibody fragment containing construct as described herein, the (ii) antibody or antibody fragment portion of the conjugate targets (detects) surface proteins of viral infected cells and (i) the cytotoxic agent portion of the conjugate eradicates (destroys) the targeted viral infected cells. Preferably, the cells to be targeted are HIV (e.g., HIV-1) infected cells and the conjugate detects/targets the HIV (e.g., HIV-1) envelope glycoprotein expressed on the HIV infected cells. Administration of the conjugates can be used to destroy viral (e.g., HIV, such as HIV- 1) infected cells in a subject, thereby leading to successful treatment (cure) of the viral (e.g., HIV) infection in the subject. Accordingly, the invention provides a method for treating a viral infection in a subject comprising administering the inventive conjugate to the subject,
thereby treating (curing) the viral infection in the subject by destroying the viral-infected cells in the subject.
[0049] Methods for conjugating the polypeptide or fusion protein (or construct containing the fusion protein) to the cytotoxic agents, chemotherapeutic agents, toxins, antibacterial compounds, and antiviral compounds, and the like are well known in the art. For example, conjugates can be made using a variety of bifunctional protein coupling agents such as N- succinimidyl-3-(2-pyridyidithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p- diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene).
[0050] Detectable agents, such as fluorescent compounds, also can be added to the polypeptide or fusion protein (or construct containing the fusion protein). Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5- dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin and the like. The polypeptide or fusion protein also can be derivatized with detectable enzymes, such as alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like. When the polypeptide or fusion protein construct is derivatized with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a detectable reaction product. The polypeptide or fusion protein construct also can be derivatized with biotin, and detected through indirect measurement of avidin or streptavidin binding.
[0051] The invention also provides a nucleic acid encoding the amino acid sequence of the polypeptide or fusion protein. The nucleic acid can comprise DNA or RNA, and can be single or double stranded. Furthermore, the nucleic acid can comprise nucleotide analogues or derivatives (e.g., inosine or phophorothioate nucleotides and the like).
[0052] The nucleic acid can be provided as part of a construct comprising the nucleic acid and elements that enable delivery of the nucleic acid to a cell, and/or expression of the nucleic acid in a cell. Such elements include, for example, expression vectors, promoters, and transcription and/or translation sequences. Suitable vectors, promoters,
transcription/translation sequences, and other elements, as well as methods of preparing such nucleic acids and constructs, are known in the art (e.g., Sambrook et al., supra; and Ausubel et al., supra).
[0053] The invention further provides a recombinant vector comprising the nucleic acid. Examples of suitable vectors include plasmids (e.g., DNA plasmids), yeast (e.g.,
Saccharomyces), and viral vectors, such as poxvirus, retrovirus, adenovirus, adeno-associated virus, herpes virus, polio virus, alphavirus, baculorvirus, and Sindbis virus. When the vector is a plasmid (e.g. DNA plasmid), the plasmid can be complexed with chitosan.
[0054] When the vector is for administration to a host (e.g., human), the vector preferably has a low replicative efficiency in a target cell (e.g., no more than about 1 progeny per cell or, more preferably, no more than 0.1 progeny per cell are produced). Replication efficiency can readily be determined empirically by determining the virus titer after infection of the target cell.
[0055] The polypeptide, fusion protein, conjugate, or construct can be administered to a mammal in the form of a cell comprising a nucleic acid encoding the polypeptide or fusion protein, optionally in the form of a vector. Thus, the invention also provides a cell comprising a vector or nucleic acid encoding the polypeptide or fusion protein from which the polypeptide or fusion protein desirably is secreted. Any suitable cell can be used.
Examples include host cells, such as E. coli (e.g., E, coli Tb-1, TG-2, DH5a, XL-Blue MRF' (Stratagene), SA2821, and Y1090), Bacillus subtilis, Salmonella typhimurium, Serratia marcescens, Pseudomonas (e.g., P. aerugenosa), N. grassa, insect cells (e.g., Sf9, Ea4), yeast (S. cerevisiae) cells, and cells derived from a mammal, including human cell lines. Specific examples of suitable eukaryotic cells include VERO, HeLa, 3T3, Chinese hamster ovary (CHO) cells, W138 BHK, COS-7, and MDCK cells. Alternatively and preferably, cells from a mammal, such as a human, to be treated in accordance with the methods described herein can be used as host cells. In one embodiment, the cell is a human B cell.
[0056] Methods of introducing vectors into isolated host cells and the culture and selection of transformed host cells in vitro are known in the art and include the use of calcium chloride-mediated transformation, transduction, conjugation, triparental mating, DEAE, dextran-mediated transfection, infection, membrane fusion with liposomes, high velocity bombardment with DNA-coated microprojectiles, direct microinjection into single cells, and electroporation (see, e.g., Sambrook et al., supra, Davis et al., Basic Methods in Molecular Biology (1986), and Neumann et al., EMBO J. 1, 841 (1982)). Desirably, the cell comprising the vector or nucleic acid expresses the nucleic acid encoding the polypeptide or fusion protein such that the nucleic acid sequence is transcribed and translated efficiently by the cell.
[0057] The polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell can be isolated. The term "isolated" as used herein encompasses compounds or compositions that have been removed from a biological environment (e.g., a cell, tissue, culture medium, body fluid, etc.) or otherwise increased in purity to any degree (e.g., isolated from a synthesis medium). Isolated compounds and compositions, thus, can be synthetic or naturally produced.
[0058] The polypeptide, fusion protein, conjugate, nucleic acid, vector, or cell can be administered to any host (e.g., mammal, preferably a human) in need thereof. As a result of administration of the polypeptide, fusion protein, conjugate, nucleic acid, vector, or cell to the mammal, viral infection (e.g., HIV infection) of the mammal is inhibited. The inventive method can prophylactically or therapeutically inhibit infection by any type of HIV, but preferably inhibits HIV-1 and/or HIV-2 infection. The inventive method can be used to inhibit infection by any HIV group (e.g., groups M and/or O), and subtype (e.g., clades A, B,
C, D, E, EA, F, and/or G).
[0059] Additionally, the polypeptide, fusion protein, conjugate, nucleic acid, vector, or cell can be used to inhibit a broad range of viruses (see, e.g., Principles of Virology:
Molecular Biology, Pathogenesis, and Control, Flint et al., eds., ASM Press: Washington,
D. C. (2000), particularly Chapter 19). Examples of viruses that may be treated in accordance with the invention include, but are not limited to, Type C and Type D retroviruses, HTLV-1, HTLV-2, FIV, FLV, SIV, MLV, BLV, BIV, equine infectious virus, anemia virus, avian sarcoma viruses, such as Rous sarcoma virus (RSV), hepatitis type A, B, C, non-A and non-B viruses, arboviruses, varicella viruses, human herpes virus (e.g., HHV-6), measles, mumps, filovirus (e.g., Ebola, such as Ebola strains Sudan, Zaire, Cote d'lvoire, and Reston), SARS, influenza, and rubella viruses.
[0060] When provided therapeutically, the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof is provided at or after the diagnosis of viral (e.g., HIV) infection.
[0061] When provided prophylactically, the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof is provided in advance of viral (e.g., HIV) infection, such as to patients or subjects who are at risk for being exposed to a virus (e.g., HIV) or who have been newly exposed to a virus (e.g., HIV). Examples of such patients and subjects include, for example, healthcare workers, fetuses, neonates, or infants (e.g., nursing infants) whose mothers are infected or at risk for being infected, intravenous
drug users, recipients of blood transfusions, blood products, or transplantation tissue, and other individuals who have been exposed to a body fluid that contains or may contain HIV. The prophylactic administration of the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof prevents, ameliorates, or delays viral (e.g., HIV) infection. In subjects who have been newly exposed to a virus (e.g., HIV) but who have not yet displayed the presence of the virus (as measured by PCR or other assays for detecting the virus) in blood or other body fluid, efficacious treatment with the polypeptide, fusion protein, conjugate, nucleic acid, vector, cell, or composition thereof partially or completely inhibits or delays the appearance of the virus or minimizes the level of the virus in the blood or other body fluid of the exposed individual.
[0062] The efficacy of the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof can be assessed in various ways well known to the skilled practitioner. For instance, one of ordinary skill in the art will understand that a polypeptide or fusion protein of the invention is efficacious in treating or inhibiting a viral (e.g., HIV) infection in a subject by observing that the polypeptide or fusion protein reduces viral load or delays or prevents a further increase in viral load. Viral loads can be measured by methods that are known in the art, for example, using PCR assays to detect the presence of viral (e.g., HIV) nucleic acid or antibody assays to detect the presence of viral (e.g., HIV) protein in a sample (e.g., blood or another body fluid) from a subject or patient, or by measuring the level of circulating anti-viral (e.g., anti-HIV) antibodies in the patient. Efficacy of the polypeptide or fusion protein treatment also can be determined by measuring the number of CD4+ T cells in the HIV-infected subject. A treatment that delays or inhibits an initial or further decrease in CD4+ T cells in an HIV-positive subject or patient, or that results in an increase in the number of CD4+ T cells in the HIV-positive subject, can be considered efficacious.
[0063] The polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell can be formulated as a composition (e.g., pharmaceutical composition) comprising the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell and a carrier (e.g., a pharmaceutically or physiologically acceptable carrier). Furthermore, the
polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition of the invention can be used in the methods described herein alone or as part of a
pharmaceutical formulation.
[0064] Compositions (e.g., pharmaceutical compositions) comprising the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell can include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like.
[0065] Suitable carriers and their formulations are described in A.R. Gennaro, ed., Remington: The Science and Practice of Pharmacy (19th ed.), Mack Publishing Company, Easton, PA (1995). Pharmaceutical carriers, include sterile water, saline, Ringer's solution, dextrose solution, and buffered solutions at physiological pH. Typically, an appropriate amount of a pharmaceutically acceptable salt is used in the formulation to render the formulation isotonic. The pH of the formulation is preferably from about 5 to about 8 (e.g., about 5.5, about 6, about 6.5, about 7, about 7.5, and ranges thereof). More preferably, the pH is about 7 to about 7.5. Further carriers include sustained-release preparations, such as semipermeable matrices of solid hydrophobic polymers containing the fusion protein, which matrices are in the form of shaped articles (e.g., films, liposomes, or microparticles). It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.
[0066] The composition (e.g., pharmaceutical composition) can comprise more than one polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell of the invention. Alternatively, or in addition, the composition can comprise one or more other
pharmaceutically active agents or drugs. Examples of such other pharmaceutically active agents or drugs that may be suitable for use in the pharmaceutical composition include anticancer agents (e.g., chemotherapeutic drugs), antibiotics, antiviral drugs, antifungal drugs, cyclophosphamide, and combinations thereof. Suitable antiviral agents (e.g., anti-HIV agents) include, but are not limited to, nucleoside/nucleotide reverse transcriptase inhibitors (e.g., lamivudine, abacavir, zidovudine, stavudine, didanosine, emtricitabine, and tenofovir), non-nucleoside reverse transcriptase inhibitors (e.g., delavirdine, efavirenz, etravirine, and nevirapine), protease inhibitors (e.g., amprenavir, fosamprenavir, atazanavir, darunavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, and tipranavir), fusion or entry inhibitors (e.g., enfuvirtide and maraviroc), integrase inhibitors (e.g., raltegravir), and combination therapies thereof.
[0067] Suitable methods of administering a polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof to hosts are known in the art. The
host can be any suitable host, such as a mammal (e.g., a rodent, such as a mouse, rat, hamster, or guinea pig, rabbit, cat, dog, pig, goat, cow, horse, primate, or human).
[0068] Administration can be topical (including ophthalmical, vaginal, rectal, intranasal, transdermal, and the like), oral, by inhalation, or parenteral (including by intravenous drip or subcutaneous, intracavity, intraperitoneal, or intramuscular injection). Topical intranasal administration refers to the delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid, vector, or fusion protein. Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation.
[0069] Formulations for topical administration include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder, or oily bases, thickeners, and the like may be necessary or desirable.
[0070] If the composition is to be administered parenterally, the administration is generally by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for suspension in liquid prior to injection, or as emulsions. Additionally, parental administration can involve the preparation of a slow- release or sustained-release system, such that a constant dosage is maintained. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives also can be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases, and the like.
[0071] Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids, or binders may be desirable.
[0072] Some of the compositions can potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids, such as
hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base, such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases, such as mono-, di-, trialkyl, and aryl amines and substituted ethanolamines.
[0073] The polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, or cell can be administered with a pharmaceutically acceptable carrier and can be delivered to the mammal's cells in vivo and/or ex vivo by a variety of mechanisms well-known in the art (e.g., uptake of naked DNA, liposome fusion, intramuscular injection of DNA via a gene gun, endocytosis, and the like).
[0074] Additionally, probiotic therapies are envisioned by the present invention. Viable host cells containing the nucleic acid or vector of the invention and expressing the fusion protein or conjugate can be used directly as the delivery vehicle for the fusion protein to the desired site(s) in vivo. Preferred host cells for the delivery of the fusion protein or conjugate directly to desired site(s), such as, for example, to a selected body cavity, can comprise bacteria. More specifically, such host cells can comprise suitably engineered strain(s) of lactobacilli, enterococci, or other common bacteria, such as E. coli, normal strains of which are known to commonly populate body cavities. More specifically yet, such host cells can comprise one or more selected nonpathogenic strains of lactobacilli, such as those described by Andreu et al., J. Infect. Dis., 171(5), 1237-43 (1995), especially those having high adherence properties to epithelial cells (e.g., vaginal epithelial cells) and suitably transformed using the nucleic acid or vector of the invention.
[0075] If ex vivo methods are employed, cells or tissues can be removed and maintained outside the body according to standard protocols known in the art. The compositions can be introduced into the cells via any gene transfer mechanism, such as calcium phosphate mediated gene delivery, electroporation, microinjection, or proteoliposomes. The transduced cells then can be infused (e.g., with a pharmaceutically acceptable carrier) or homotopically transplanted back into the mammal per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a mammal.
[0076] The exact amount of the composition required to treat a viral infection (e.g., HIV infection) will vary from mammal to mammal, depending on the species, age, gender, weight, and general condition of the mammal, the nature of the virus, the existence and extent of viral
infection, the particular fusion proteins, nucleic acid, vector, or cell used, the route of administration, and whether other drugs are included in the regimen. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein. Effective dosages and schedules for administering the nucleic acid molecules, vectors, cells, and fusion proteins of the invention can be determined empirically, and making such determinations is within the skill in the art. The dosage ranges for the administration of the compositions are those large enough to produce the desired effect; however, the dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Dosage can vary, and can be
administered in one or more (e.g., two or more, three or more, four or more, or five or more) doses daily, for one or more days. The composition can be administered before viral (e.g., HIV) infection or immediately upon determination of viral (e.g., HIV) infection and continuously administered until the virus is undetectable.
[0077] The polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof is administered to a host (e.g., mammal, such as a human) in an amount effective to prophylactically or therapeutically inhibit an HIV infection. The efficacy of the polypeptide, fusion protein, conjugate, construct, nucleic acid, vector, cell, or composition thereof as an HIV infection inhibitor may be determined by in vivo or in vitro parameters known in the art.
[0078] Any suitable dose of the polypeptide fusion protein, conjugate, nucleic acid, vector, cell, or composition thereof can be administered to a host. The appropriate dose will vary depending upon such factors as the host's age, weight, height, sex, general medical condition, previous medical history, and viral (e.g., HIV) infection progression and can be determined by a clinician. For example, the polypeptide, fusion protein, or conjugate can be administered in a dose of about 1 μg/kg to up to 100 mg/kg of body weight or more per day (e.g., 5 με/1¾, 10 μξ/kg, 50 ^gl g, 100 \xgl g, 200 xgl g, 300 \xgl g, 400 500 짽,
600 xgl g, 700 μ /kg, 800 μ^, 900 μ§¾, 1 mg/kg, 2 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, and ranges thereof) to the host (e.g., mammal, such as a human). Several doses (e.g., 1 , 2, 3, 4, 5, 6, or more) can be provided (e.g., over a period of weeks or months).
[0079] When the vector is a viral vector, a suitable dose can include about 1 x 105 to about 1 x 1012 (e.g., 1 x 106, 1 x 107, 1 x 108, 1 x 109, 1 x 1010, 1 x 1011, and ranges thereof)
plaque forming units (pfus), although a lower or higher dose can be administered to a host. For example, about 2 x 108 pfus can be administered (e.g., in a volume of about 0.5 niL).
[0080] The inventive cells can be administered to a host in a dose of between about 1 x 105 and 2 x 1011 (e.g., 1 x 106, 1 x 107, 1 x 108, 1 x 109, 1 x 1010, and ranges thereof) cells per infusion. The cells can be administered in, for example, one to three (e.g., two) infusions. In addition to the administration of the cells, the host can be administered a biological response modifier, such as interleukin 2 (IL-2).
[0081] The polypeptide or fusion protein (or construct containing the fusion protein) can be used in combination with other well-known viral (e.g., HIV) therapies and prophylactic vaccines already in use. The combination of the fusion protein of the invention can generate an additive or a synergistic effect with current treatments. The polypeptide or fusion protein (or construct containing the fusion protein) of the invention can be combined with other HIV and AIDS therapies and vaccines, such as highly active antiretroviral therapy (HAART), which comprises a combination of protease inhibitors and reverse transcriptase inhibitors, azidothymidine (AZT), structured treatment interruptions of HAART, cytokine immune enhancement therapy (e.g., interleukin (IL)-2, IL-12, CD40L + IL-12, IL-7, HIV protease inhibitors (e.g., ritonavir, indinavir, and nelfinavir, etc.), and interferons (IFNs)), cell replacement therapy, recombinant viral vector vaccines, DNA vaccines, inactivated virus preparations, immunosuppressive agents, such as Cyclosporin A, cyanovirin therapy (see, e.g., U.S. Patent No. 6,015,876), scytovirin therapy (see, e.g., U.S. Patent No. 7,491,798), and griffithsin therapy (see, e.g., U.S. Patent Application Publication 2009-0092557). Such therapies can be administered in the manner already in use for the known treatment providing a therapeutic or prophylactic effect (see, e.g., Silvestri et al. Immune Intervention in AIDS. In: Immunology of Infectious Disease, H.E. Kauffman, A. Sher, and R. Ahmed eds., ASM Press, Washington DC (2002)).
[0082] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
EXAMPLE 1
[0083] This example describes the identification of single domain CD4 (Dl) with improved soluble expression, stability, and specificity.
[0084] Structure-guided cavity filling and library screening were used to identify Dl mutants with improved soluble expression, stability and specificity. The screening yielded two mutants: mD1.22 (SEQ ID NO: 1) and mD1.23 (SEQ ID NO: 2) (see Figure 1).
[0085] As depicted in Table 1 , the mutants were significantly more soluble in E. coli periplasm and PBS than the previously identified Dl mutant (mD1.2; Chen et al., J. Virol., 85: 9395-9405 (201 1)).
Table 1. Properties of single domain CD4 mutants.
ND = not determined
EXAMPLE 2
[0086] This example demonstrates the characterization of mDl .22 and mDl .23.
[0087] The binding characteristics of mD 1.2 (Chen et al., 2011 , supra), mD 1.22 (SEQ ID NO: 1), and mDl .23 (SEQ ID NO: 2) with HIV-1 gpl40 were assessed at different Dl concentrations.
[0088] ELISAs were performed with gpl40con-s, which is a consensus gpl40 designed by aligning >1,000 sequences of group M (see Liao et al., Virology, 353: 268-282 (2006)), and gpl40cHi2.o544.2- Bound mDl .2 and the mDl .22 and mDl .23 mutants were detected by HRP- conjugated anti-hexahistidine tag antibody (Sigma-Aldrich, St. Louis, MO).
[0089] As shown in Figs. 3A and 3B, both mutants were cross-reactive against the tested gpl40s.
[0090] Binding of genetically diverse HIV-1 Envs also was analyzed by surface plama resonance (SPR) on a Biacore XI 00 appartus (GE Healthcare) using a single-cycle approach. Briefly, purified HIV-1 gpl40 was diluted in sodium acetate (pH 5.0) and immobilized directly onto a CM5 sensor chip via the standard amine coupling method. The reference cell was injected with N-hydroxysuccinimide-l-ethyl-3-(3-dimethyaminopropy)carbodiimide and ethanolamine without injection of gpl40. The Dl mutants and D1D2 were diluted with running buffer HSB-EP (100 mM HEPES (ph 7.4), 1.5 M NaCl, 30 mM EDTA, 0.5%
surfactant 20). All analytes were tested at 500, 100, 20, 4, and 0.8 nM concentrations.
Kinetic contants were calculated from the sensograms fitted with the monvalent binding model of the BiocoreXlOO Evlauation software 2.0.
[0091] In the SPR analysis with four HIV-1 Env gpl40s, mDl .22 showed affinities comparable to, or higher than, those of mDl .2 (see Table 8).
EXAMPLE 3
[0092] This example demonstrates that the D 1 mutants maintain the functional activity of full-length CD4.
[0093] CD4 induces conformational changes in gpl20 leading to exposure of CD4- inducible (CD4i) epitopes. To determine whether the Dl mutants induce such
conformational changes, an CD4i antibody-based fusion protein, m36hlFc (see Chen et al., Proc. Natl. Acad. Sci. USA, 105: 17121-17126 (2008)), was tested for binding to gpl40Con-s in the absence or presence of mDl .2 (SEQ ID NO: 3), mDl .22 (SEQ ID NO: 1), or mD1.23 (SEQ ID NO: 2). The two-domain human CD4 (D1D2; SEQ ID NO: 5) was used a positive control and Fab bl2, which is an HIV-1 broadly neutralizing antibody targeting the CD4- binding site on gpl20 (see Roben et al, J. Virol., 68: 4821-4828 (1994)), was used as the negative control.
[0094] Binding of m36hlFc to gpl40con-s was increased in the presence of the Dl mutants relative to the controls (see Fig. 4). Additionally, the binding m36hlFc to gpl40con-s was increased or comparable to the binding observed in the presence of D1D2 and mDl .2, respectively (see Fig. 4).
EXAMPLE 4
[0095] This example demonstrates the further characterization of the Dl mutants.
[0096] The secondary structure and thermal stability of mD1.2 (SEQ ID NO: 3), mD1.22 (SEQ ID NO: 1), and mD1.23 (SEQ ID NO: 2) were determined by circular dichroism (CD) spectroscopy. The purified proteins were dissolved in PBS at the final concentration of 0.33 mg/niL, and the CD spectra were recorded on AVIV Model 202 CD Spectrometer (Aviv Biomedical). Wavelength spectra were recorded at 25 °C using a 0.1-cm path-length cuvette for native structure measurements. Thermal stability was measured at 216 nm by recording the CD signal in the temperature range of 25-90 °C with heating rate 1 °C/min. The temperature was recorded with an external probe sensor and the temperature inside the
microcuvette was calculated by calibration; it was about 2-3 °C (range from 1.9 to 3.8 °C for temperatures from 20 to 80 °C) lower than the one measured by the external sensor. After heating, wavelength spectra were recorded at 90 °C.
[0097] As evidenced by Fig. 5 A, mDl .22 and mDl .23 consist primarily of β-strand secondary structures. mDl .22 has higher thermal stability than mDl .2 and mDl .23 (see Fig. 5B).
[0098] Similar to mDl .2, mDl .22 and mDl .23 were uniformly monomeric in PBS at pH 7.4 as determined by size-exclusion chromatography. D1D2 also was monomeric but it was not eluted as a single peak (see Fig. 6 A). mDl .22 did not tend to aggregate at high concentrations (10 mg/niL) as shown by dynamic light scattering (see Fig. 6B).
EXAMPLE 5
[0099] This example demonstrates the characterization of Fc fusion proteins comprising the Dl mutants.
[0100] Fc-fusion proteins of D1D2, DlD2m (with A55V mutation; SEQ ID NO: 6), mDl .2, and mD1.22 (DlD2Fc, DlD2mFc, mD1.2Fc, and mD1.22Fc, respectively) were prepared using routine methods.
[0101] The binding of MHC-expression cells - human blood cell lines BJAB (B cell) and SUP-T1 (T cell) - was accessed for m36hlFc (negative control), DlD2Fc, DlD2mFc, mD1.2Fc, and mD1.22Fc. As evidenced by Figs. 7 and 8B, Fc fusions of mD1.22 or DlD2m show decreased binding with MHC-expression cells relative to the other fusion proteins.
[0102] To determine if the A55V mutation results in conformational changes, interaction with a CD4 Dl -specific antibody (D9) was assessed. As shown in Fig. 9, the presence of the A55V mutation in mDl .22Fc and DlD2mFc largely decreased binding with the D9 antibody. This suggests that the mutation induces conformation changes in Dl . However, as noted above, the presence of the A55V mutation results in increased binding to HIV-1 gpl40 (see Fig. 8A).
EXAMPLE 6
[0103] This example demonstrates the characterization of bispecific multivalent fusion proteins comprising mD1.22.
[0104] Bispecific multivalent fusion proteins of mDl .22 (SEQ ID NO: 1) and m36.4 as exemplified in Fig. 2 (2Dm2m, 4Dm2m, and 6Dm2m) were prepared. m36.4 (SEQ ID NO:
15) is an engineered single human antibody domain targeting a CD4i epitope on HIV-1 gpl20.
[0105] In each of the bispecific multivalent fusion proteins, A corresponds to m36.4, B corresponds to mDl .22, C corresponds to a light chain constant region, D corresponds to a heavy chain constant region, and E corresponds to an Fc region. In particular, 2Dm2m comprises two fusion proteins comprising SEQ ID NO: 18 and two fusion proteins comprising SEQ ID NO: 19. 4Dm2m comprises two fusion proteins comprising SEQ ID NO: 20 and two fusion proteins comprising SEQ ID NO: 21. 6Dm2m comprises two fusion proteins comprising SEQ ID NO: 22 and two fusion proteins comprising SEQ ID NO: 23.
[0106] Similar to the results described in Example 5, the mDl .22-m36.4 multivalent fusion proteins showed much lower binding to MHC-expressing BJAB cells than DlD2Fc (see Fig. 10).
[0107] To determine the potency and breadth of HIV-1 neutralization by the Dl mutants, viruses pseudotyped with Envs from HIV-1 isolates representing clades A-E and using either CCR5 (R5) or CXCR4 (X4) or both (R5X4) as a coreceptor were included. Pseudoviruses were derived from 293T cells and a neutralization assay was performed in duplicate using HOS-CD4-CCR5 (for all R5 and dual tropic viruses) or HOS-CD4-CXCR4 cell lines as described in Chen et al., Proc. Natl. Acad. Sci. USA, 105: 17121-17126 (2008)).
Luminescence was measured 48 hours post-infection and the percentage neutralization was calculated by the following formula: (1 - average RLU of inhibitor-containing wells/average RLU or virus-only wells) x 100. IC50 and ICgo of neutralization were assigned for the inhibitor concentration at which 50% and 90% neutralization were observed, respectively.
[0108] As shown in Tables 2 and 3, mDl .22 and mDl .22-containing fusion proteins neutralized HIV-1 primary isolates from several different clades. Significantly, 4Dm2m and 6Dm2m were more potent than broadly neutralizing monoclonal antibody VRCO 1 (see Table 3).
[0109] Additionally, mDl .22 and mDl .22-containing fusion proteins inhibited HIV-1 envelope glycoprotein-mediated cell fusion (see Tables 4 and 5). As shown in Table 5, 4Dm2m and 6Dm2m are more potent than VRCOl in inhibiting HIV-1 envelope glycoprotein mediated cell-cell fusion.
[0110] In a TZM-bl cell-based assay (see Brown et al., Virology, 375: 529-538 (2008)) where TZM-bl cells and HIV-1 isolates randomly selected from each clade from A to D, AE, and AG (total n=12) were used, 4Dm2m and 6Dm2m were much more potent than bl2 and
CD4-Ig and about 10-fold more potent than VRCOl when the geometric means of their IC50s and IC90S were compared (see Table 6).
[0111] In another TZM-bl cell-based assay using a panel of pseudo viruses with Envs derived from 41 HIV-1 isolates predominantly circulating in China (see Yao et al., J. Biol. Chem., 287: 6788-6796 (2012); and Shang et al., J Biol. Chem., 286: 14531-14541 (201 1)), 4Dm2m and 6Dm2m were compared to T20 (enfuvirtide), which is an FDA-approved peptide inhibitor derived from the HIV-1 Env gp41 C-terminal heptad repeat (CHR), C34, which is another potent CHR peptide inhibitor, and CD4-Ig for neutralizing activities against the panel (see Table 7). 4Dm2m and 6Dm2m neutralized all viruses with IC50 geometric mean values of approximately 0.20 nM, which are about 50-fold (P=0.002, Student's paired t test), 16-fold (PO.001 , Student's pairent t test), and 200-fold (PO.001 , Student's paired t test) lower than those (11, 3.5, and 42 nM) of T20, C34, and CD4-Ig respectively (see Table 7). The superior potencies of 4Dm2m and 6Dm2m also were observed when the IC90S were compared.
[0112] 4Dm2m and 6Dm2m also have been shown to not enhance HIV-1 infectivity at low concentrations, which is in contrast to D1D2 (see Fig. 1 1).
EXAMPLE 7
[0113] This example deomonstrates thet solublility, stability, and aggregration propensity of the bispecific multivalent fusion proteins.
[0114] To evaluate the potential for further development as drugs, several drug-related properties, including solubility, stability, and aggregation propensity were tested. 4Dm2m and 6Dm2m in PBS were concentrated to 25.0 and 25.9 mg/ml, respectively, without visible precipitation after high-speed centrifugation. They were stored at 4 °C for 2 weeks, and no additional precipitation was observed, suggesting high solubility of the proteins.
[0115] To test whether soluble aggregates of 4Dm2m and 6Dm2m formed during prolonged incubation, dynamic light scattering (DLS) was used. Proteins concentrated to 10 mg/ml in PBS were stored at 80 °C and slowly thawed on ice before measurements. The results showed that the particles of 4Dm2m and m.909, a control human antibody in the IgGl format (see Feng et al., Arthritis Res. Ther. 13: R59 (2011)), were predominantly small (average diameters, 16.3 and 12.7 nm, respectively). The minor aggregates of 4Dm2m disappeared within the first day of incubation at both 4 °C and 37 °C, while m909 aggregation continued to occur following the incubation at 37 °C. In comparison, about 30 to
50% of the CD4-Ig particles were large, with average diameters of approximately 100 nm, and the aggregation persisted during the whole period of incubation. 6Dm2m partially aggregated after the freeze-thaw cycle; although the aggregation was weakened following the incubation, it led to a relatively wide particle size distribution.
[0116] These results suggest that like typical IgGls, 4Dm2m has a low aggregation propensity, which is lower than that of CD4-Ig.
[0117] The proteins were then assessed for their stability against degradation during 15 days of incubation with PBS (see Fig. 12A) or human serum (see Fig. 12B) at 37 °C.
Incubation in PBS for 10 days caused no significant decrease in the amount of functional 4Dm2m, whereas about 20% and 30%, respectively, of 6Dm2m and CD4-Ig lost binding activity to gpl40con-s (see Fig. 12A). 4Dm2m began to be degraded and 6Dm2m continued to be degraded thereafter, while CD4-Ig appeared to be stable. Finally, about 90% of 4Dm2m remained functional, slightly more than those (80%) of 6Dm2m and CD4-Ig.
[0118] With human serum, levels of all proteins declined at similar rates during the first 5 days of incubation (see Fig. 12B). However, degradation of 4Dm2m and 6Dm2m became slower than that of CD4-Ig during the next 5 days of incubation. At the end of the measurement period, the level of CD4-Ig that retained binding activity was slightly higher than that for functional 4Dm2m and 6Dm2m, but the differences in the amounts were not statistically significant.
Table 2. Neutralization of pseudotyped HIV-1 by mD1.22 of different valences.
Vims Clade Tropism m36.4 mD1.22 mD1.22Fc 2Dm2m 4Dm2m 6Dm2m
ICiQ3 IC0b IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
Bal B R5 16±1 75 ± 18 2.1 ±0.1 5.2±0.2 0.40±0.00 1. ±0.2 0.34±0.15 0.59±0.05 0.12±0.01 0.36±0.06 0.063±0.004 0.22±0.02
JRFL B R5 18 ± 5 106±4 2.9±0.4 25 ± 1 1.2 ±0.1 25±6 0.090±0.008 0.59±0.06 0.060±0.014 0.29±0.09 0.043±0.004 0.21 ±0.01 a Antibody concentration (nM) resulting in 50% inhibition of virus infection.
b Antibody concentration (nM) resulting in 90% inhibition of virus infection.
Table 3. Neutralization of HIV- 1 pseudotyped with Envs from different clades by 4Dm2m, 6Dm2m, and bnmAbs.
Virus Clade Tropism 2G12 VRCOl 4Dm2m 6Dm2m
ICso" ICso IC 0 ICso IC90 ICso IC90
92UG037.8 A R5 0.53 ±0.10 63 ±4 0.33 ±0.11 3.8 ±4.3 0.051 ±0.001 0.45 ±0.01 0.14 ±0.08 2.1 ±0.6
Bal B R5 3.1 ±0.0 41 ± 1 0.11 ±0.04 0.56 ±0.01 0.15 ±0.04 0.50 ± 0.07 0.12 ±0.01 0.38 ±0.02
JRFL B R5 3.0 ±0.5 13 ± 3 0.31 ±0.21 0.82 ± 0.40 0.14 ±0.01 0.39 ± 0.04 0.10 ±0.01 0.43 ± 0.04
JRCSF B R5 0.58 ±0.17 9.3 ± 8.0 0.28 ±0.18 5.6 ±2.1 0.29 ±0.18 3.0 ±2.9 0.21 ±0.14 1.0 ± 0.1
AD8 B R5 1.2 ±0.1 18 ± 3 0.36 ±0.13 4.3 ± 0.4 0.13 ±0.01 0.74 ± 0.06 0.11 ±0.01 0.60 ± 0.08
R2 B R5 0.68 ±0.11 4.6 ±0.1 0.34 ±0.01 4.4 ±0.1 0.028 ±0.011 0.43 ±0.18 O.021 0.14 ±0.04
IIIB B X4 1.5 ±0.0 9.3 ± 2.4 0.26 ±0.01 0.83 ± 0.04 0.037 ±0.001 0.10 ±0.01 .021 0.086 ± 0.006
NL4-3 B X4 1.3 ±0.2 18 ± 10 0.25 ± 0.02 2.6 ±0.6 0.094 ± 0.002 0.15 ±0.02 0.068 ± 0.004 0.19 ±0.02
89.6 B R5X4 1.3 ± 1.1 43 ± 11 0.37 ±0.10 14±2 O.021 O.021 O.021 O.021
GXC C R5 - 2.1 ±0.1 6.6 ±4.8 0.61 ± 0.36 4.0 ±0.0 0.63 ±0.06 1.7 ± 0.1
Z2Z6 D R5 0.70 ±0.01 14 ±2 0.11 ±0.01 0.85 ±0.14 0.14 ±0.04 1.1 ±0.1 0.045 ± 0.006 0.50 ± 0.00
CM243 E R5 - - 0.53 ±0.11 9.5 ±2.1 0.29 ±0.11 1.2 ±0.6 0.15 ±0.05 1.8 ±0.4
GXE E R5 - - 2.0 ± 0.4 26 ±23 0.83 ±0.11 8.2 ± 1.3 0.83 ±0.38 6.3 ± 5.2
Arithmetic means'' 1.4 23 0.57 6.1 0.22 1.6 0.19 1.2
Geometric means ,d 1.2 17 0.37 3.4 0.12 0.56 0.083 0.46
" Antibody concentration (nM) resulting in 50% inhibition of virus infection.
* Antibody concentration (nM) resulting in 90% inhibition of virus infection.
'' No significant neutralization at the highest antibody concentration (67 nM) tested.
d ' Arithmetic and geometric means were calculated for all viruses including those with values <0.021 nM, which were assigned a value of 0.01. The means for 2G12 were calculated based on the values with 10 isolates that were significantly neutralized.
Table 4. Inhibition of HIV- 1 Env-mediated cell-cell fusion by mD1.22 of different valences.
Virus Clade Tropism m36.4 mD1.22 mD1.22Fc 2Dm2m 4Dm2m 6Dm2m
IC5f IC,c IC5< IC«, IC5( IC9C IC5f IC9t ICsc IQio ICsc
Bal B R5 11 ± 1 235±49 21 ±0 108±4 24±4 135 ±21 21 ± 6 113 ± 39 4.1 ±0.1 13 ± 3 3.0±0.0 5.0±0.8
JRFL B R5 128±5 1075 ± 35 66 ± 1 208±4 66 ± 1 >222 7.5±0.0 80±9 1.6± 0.7 11±2 0.46±0.07 10 ± 3 a Antibody concentration (nM) resulting in 50% inhibition of cell-cell fusion.
b Antibody concentration (nM) resulting in 90% inhibition of cell-cell fusion.
Table 5. Inhibition of HIV- 1 Env-mediated cell-cell fusion by 4Dm2m, 6Dm2m, and bnmAbs.
Virus Clade Tropism 2G12 VRCOl 4Dm2m 6Dm2m
IC5011 IC90 IC50 IC90 IC50 IC90 IC50 IC90
Bal B R5 38 ±31 >67 2.6 ±0.0 24 ±2 4.1 ±0.1 12 ±0 2.3 ± 0.2 6.7 ±2.2
JRFL B R5 14 ±2 67 ± 5 3.1 ±0.6 21 ± 1 3.6 ±0.2 8.8 ±0.4 2.3 ±0.3 5.8 ±1.1 a Antibody concentration (nM) resulting in 50% inhibition of cell-cell fusion.
b Antibody concentration (nM) resulting in 90% inhibition of cell-cell fusion.
Table 6. Neutralization of HIV- 1 in TZM-bl cell-based assays
Virus Clade Tropism ICso (nMf IC90 (nM)°
bl2* VRCOl* DlD2Fc 4Dm2m 6Dm2m bl2 VRCOl DlD2Fc 4Dm2m 6Dm2m
KNH1088.EC5 A R5 117 3.0 >250 0.48 1.0 >167 18 >250 18 33 NH1144.EC1 A R5 >167 2.2 4.8 0.081 0.11 >167 9.5 42 1.0 1.1
Bal.ECl TC B R5 1.2 0.39 0.60 0.057 0.045 3.6 5.2 3.2 0.22 0.20
BZ167.ec9 B X4 14 6.4 13 0.077 0.10 >167 31 60 0.50 0.76
GS-015.EC12 C R5 0.085 >167 0.20 0.022 0.027 1.6 >167 3.2 0.17 0.17
PBL286.VRC36aPV C R5 4.0 2.1 87 2.0 2.1 19 10 >250 14 12
A07412VRC12A D R5 12 1.3 57 0.75 0.76 >167 6.0 >250 5.7 6.1
57128.VRC18 D R5 2.3 >167 5.4 0.40 0.44 30 >167 41 2.8 2.6
CM240.EC1 AE R5 82 0.66 20 0.45 0.40 >167 11 >250 3.7 3.6
Nl 1046.e3 PV AE R5 138 4.2 183 3.5 3.1 >167 18 >250 27 30
C AMOO 15BB Y.EC3 AG R5 81 21 41 0.72 1.4 >167 >167 >250 7.4 7.6
55815.EC3 AG R5 >167 0.33 6.2 0.084 0.077 >167 2.6 116 0.61 0.67
Arithmetic meanc 71 37 60 0.72 0.80 138 59 172 6.8 8.2
Geometric meane 17 4.2 14 0.28 0.32 67 21 82 2.4 2.6
"The assay was performed in duplicate. Results are presented as mean without standard deviation. Means are calculated only when the difference between results for the duplicate assays was within 3 -fold.
The bnAbs bl2 and VRCOl used in the neutralization assay are in IgGl format.
c Arithmetic and geometric means were calculated for all viruses including those with values >167 nM, which were assigned a value of 200, and those with values >250, which were assigned a value of 300.
Table 7. Neutralization of HIV- 1 isolates predominantly circulating in China in TZM-bl cell-based assays
Vims Clade Tropism IC50 (nM)° 10» (nM)°
T20 C34 DlD2Fc 2Dm2m 4Dm2m 6Dm2m T20 C34 DlD2Fc 2Dm2m 4Dm2m 6Dm2m
CH64 BC R5 3.1 1.2 48 1.7 0.17 0.13 25 6.7 >250 14 1.6 0.80
CH70 BC R5 65 7.6 7.3 0.40 0.11 0.09 >750 84 109 3.1 1.2 0.67
CH91 BC R5 8.6 2.3 35 3.7 0.39 0.27 310 12 >250 56 10 3.5
CH110 BC R5 4.3 0.78 28 0.93 0.11 0.09 262 6.3 >250 8.7 0.83 0.58
CH114 BC R5 102 5.4 23 1.5 0.11 0.18 >750 25 198 19 4.0 1.9
CHI 17 BC R5 2.3 0.60 27 5.4 0.33 0.22 34 3.2 >250 62 15 5.1
CHI 19 BC R5 2.0 3.3 85 2.7 0.17 0.13 25 20 >250 25 3.4 1.1
CH120 BC R5 11 4.6 104 4.3 0.33 0.27 443 39 >250 46 6.6 3.5
CNE7 BC R5 4.3 6.4 19 1.5 0.18 0.14 58 22 161 8.1 1.8 1.2
CNE15 BC R5 14 3.8 106 3.0 0.29 0.17 157 22 >250 20 2.6 1.3
CNE16 BC R5 14 11 11 0.77 0.08 0.07 169 51 229 8.5 1.2 0.71
CNE20 BC R5 5.5 3.3 65 11 0.05 0.29 41 14 >250 >100 5.3 2.9
CNE23 BC R5 15 2.1 >250 5.4 0.49 0.48 228 18 >250 35 4.9 9.9
CNE30 BC R5 26 14 17 0.58 0.07 0.06 285 110 211 3.6 0.44 0.31
CNE40 BC R5 4.9 0.77 0.06 0.04 0.01 0.01 108 7.8 0.50 0.33 0.11 0.09
C E46 BC R5 26 6.4 99 3.8 0.27 0.21 743 115 >250 81 9.4 2.8
CNE47 BC R5 4.9 1.9 152 1.5 0.11 0.12 42 14 >250 30 2.8 1.2
CNE49 BC R5 9.1 2.3 21 0.40 0.05 0.05 236 12 224 2.6 0.56 0.44
CNE53 BC R5 51 2.0 14 2.8 0.24 0.47 721 23 >250 95 5.5 12
CNE68 BC R5 32 2.2 9.7 0.40 0.11 0.04 321 12 133 4.5 0.78 0.89
CNE1 B' X4 1.6 0.73 197 0.47 0.11 0.22 17 6.8 >250 4.1 0.61 2.2
CNE4 B' R5 1.7 6.3 3.9 0.40 0.11 0.13 14 23 24 0.40 2.4 0.80
CNE6 B' R5 1.4 1.6 68 1.7 0.33 0.22 15 15 192 6.9 2.3 1.4
CNE9 B' R5 1.7 0.87 9.9 1.1 0.22 0.22 14 5.8 63 7.0 3.2 1.7
CNE11 B' R5 3.5 4.6 >250 1.8 0.33 0.36 36 42 >250 11 2.6 3.4
CNE14 B' R5 9.7 3.9 105 0.80 0.17 0.18 305 17 248 4.13 2.4 1.6
CNE57 B' X4 2.5 2.0 250 2.1 1.2 0.71 24 14 >250 >100 19 22
CNE64 B' R5 1.9 5.1 12 1.4 0.56 0.22 16 21 113 6.5 3.2 1.5
CNE17 C R5 42 3.2 11 2.4 0.11 0.13 676 82 231 36 2.4 0.84
CNE58 C R5 54 2.0 >250 10 2.1 1.1 745 13 >250 >100 >28 >28
CNE65 C R5 5.9 3.1 15 1.1 0.28 0.22 78 16 115 12 3.3 1.5
CNE66 C R5 129 2.1 159 1.2 0.17 0.09 729 11 >250 >100 7.7 3.1
CNE3 AE R5 5.6 7.1 >250 1.9 0.39 0.31 38 71 >250 11 2.8 2.0
CNE5 AE R5 2.1 5.9 94 1.8 0.67 0.53 19 63 236 15 8.7 5.9
CNE55 AE R5 26 7.9 213 5.9 0.45 0.46 549 103 >250 42 10 5.1
C E59 AE R5 1.4 3.4 10 0.93 0.17 0.18 17 28 220 16 2.7 3.8
CNE107 AE X4 3.8 2.8 135 3.7 0.52 0.89 45 32 >250 33 18 21
AE20 AE R5 212 7.4 50 1.5 0.72 0.49 572 69 >250 10 5.8 4.1
AE03 AE R5 304 24 >250 5.7 0.67 0.40 510 85 >250 58 12 15
YN192.31 AE R5 42 27 155 5.7 0.89 2.4 336 225 >250 65 21 19
GX2010.36 AE R5 255 . 15 12 4.7 0.11 0.13 >750 165 >250 90 18 6.8
Arithmetic mean* 37 5.3 94 2.6 0.34 0.32 277 42 242 38 6.2 5.0
Geometric mean6 11 3.5 42 1.7 0.22 0.20 123 25 195 17 3.5 2.4
"The assay was performed in duplicate. Results are presented as mean without standard deviation. Means are calculated only when the difference between results for the duplicate assays was within 3-fold.
6 Arithmetic and geometric means were calculated for all viruses including those with values >750 nM, which were assigned a value of 800, those with values >250 nM, which were assigned a value of 300, those with values >100, which were assigned a value of 150, and those with values >28 nM, which were assigned a value of 30.
Table 8. Binding kinetics of mDl.2 and mD1.22 to HIV-1 g l40 as measured by SPR
HIV-1 g l40 Clade mDl.2 mD1.22
Ka(M V) Kd(sl) KD (nM) Ka(M V) Kd(- ¾(nM)
Gpl40Con-s Consensus" 1.7 x 10 9.3 10"4 5.4 1.7 105 7.7 10"4 4.4
Gpl40MS A 4.2 105 1.0 10"4 0.24 3.8 x 105 7.3 x lo-5 0.19
Gpl40896 B 3.4 x 105 4.0 x 10"4 1.2 2.5 x 105 2.1 x lo-4 0.87
Gpl40CH12.0544.2 B 1.5 105 1.1 x 10"4 0.72 1.2 x 105 2.0 lo-5 0.17 a A consensus g l40 designed by aligning > 1,000 sequences of HIV-1 group M.
Ka, association rate constant.
Kd, dissociation rate constant.
KD, equilibrium dissociation constant.
[0119] The examples described herein demonstrate the identification of new Dl mutants. In particular, mDl .22 has improved soluble expression and stability, showed no measurable interaction with human blood B and T cell lines, and preserved binding and cross-reactivity with HIV-1 gpl20. mD1.22-m36.4 fusion proteins have been shown to be potent HIV-1 neutralizers and multivalent mD1.22-m36.4 fusion proteins do not tend to enhance HIV-1 infectivity. Thus, the newly identified mutants can be used for HIV-1 prevention and therapy, and also can serve as valuable tools to study the mechanism of HIV-1 entry and biological functions of CD4 in immune responses.
[0120] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0121] The use of the terms "a" and "an" and "the" and "at least one" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term "at least one" followed by a list of one or more items (for example, "at least one of A and B") is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly
contradicted by context. The terms "comprising," "having," "including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to,") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0122] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
1. A polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
2. A composition comprising the polypeptide of claim 1 and a carrier.
3. A fusion protein comprising (i) the amino acid sequence of SEQ ID NO: 1 and (ii) one or more fusion partners, wherein the one or more fusion partners optionally is fused to the amino acid sequence of (i) via a linker.
4. A fusion protein comprising (i) the amino acid sequence of SEQ ID NO: 2 and (ii) one or more fusion partners, wherein the one or more fusion partners optionally is fused to the amino acid sequence of (i) via a linker.
5. The fusion protein of claim 3 or 4, wherein the one or more fusion partners is an engineered antibody domain (eAd), an HIV envelope glycoprotein, an Fc region or portion thereof, an immunoglobulin heavy chain constant region, an immunoglobulin light chain constant region, or a combination thereof.
6. The fusion protein of claim 5, wherein the one or more fusion partners is an eAd.
7. The fusion protein of claim 6, wherein the eAd binds to an HIV envelope glycoprotein.
8. The fusion protein of claim 7, wherein the eAd comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-16.
9. The fusion protein of claim 5, wherein the one or more fusion partners is an HIV envelope glycoprotein.
10. The fusion protein of any one of claims 7-9 wherein the HIV envelope glycoprotein is gpl 20.
1 1. The fusion protein of any one of claims 7-10, wherein the HIV is HIV-1.
12. The fusion protein of claim 5, wherein the one or more fusion partners is an Fc region or portion thereof.
13. A fusion protein comprising: A-(optional linker)-C-(optional linker)-B or
B-(optional linker)-D-(optional linker)-E-(optional linker)-B
wherein A is an antibody or antibody fragment, B is the polypeptide of claim 1 , C is an immunoglobulin light chain constant region, D is an immunoglobulin heavy chain constant region, and E is an Fc region or portion thereof.
14. The fusion protein of claim 13, wherein the antibody or antibody fragment of A comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12- 16.
15. The fusion protein of any one of claims 12-14, wherein the Fc region or portion thereof is an IgGl Fc region.
16. The fusion protein of claim 15, wherein the Fc region or portion thereof comprises SEQ ID NO: 7 or SEQ ID NO: 8.
17. The fusion protein of any one of claims 3-16, wherein the linker comprises one or more G4S motifs.
18. The fusion protein of any one of claims 3-17, wherein the linker comprises the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 1 1.
19. A composition comprising the fusion protein of any one of claims 3-18 and a carrier.
20. A nucleic acid encoding the polypeptide of claim 1.
21. A nucleic acid encoding the fusion protein of any one of claims 3-18.
22. A recombinant vector comprising the nucleic acid of claim 20 or 21.
23. A cell comprising the nucleic acid of claim 20 or 21 or the vector of claim 22.
24. A composition comprising (i) the nucleic acid of claim 20 or 21, the vector of claim 22, or the cell of claim 23, and (ii) a carrier.
25. A construct comprising two fusion proteins of A-(optional linker)-C (Formula (III)), and two fusion proteins of B-(optional linker)-D-(optional linker)-E (Formula (IV)), wherein A is an antibody or antibody fragment, B is the polypeptide of claim 1 , C is an immunoglobulin light chain constant region, D is an immunoglobulin heavy chain constant region, and E is an Fc region or portion thereof.
26. The construct of claim 25, wherein the fusion protein of Formula (III) comprises SEQ ID NO: 19 and the fusion protein of Formula (IV) comprises SEQ ID NO: 18.
27. A construct comprising two fusion proteins of A-(optional linker)-C (Formula (III)), and two fusion proteins of B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula (II)), wherein A is an antibody or antibody fragment, B is the polypeptide of claim 1, C is an immunoglobulin light chain constant region, D is an immunoglobulin heavy chain constant region, and E is an Fc region or portion thereof.
28. The construct of claim 27, wherein the fusion protein of Formula (III) comprises SEQ ID NO: 21 and the fusion protein of Formula (II) comprises SEQ ID NO: 20.
29. A construct comprising two fusion proteins of A-(optional linker)-C-(optional linker)-B (Formula (I)), and two fusion proteins of B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula (II)),
wherein A is an antibody or antibody fragment, B is the polypeptide of claim 1 , C is an immunoglobulin light chain constant region, D is an immunoglobulin heavy chain constant region, and E is an Fc region or portion thereof.
30. The construct of claim 29, wherein the fusion protein of Formula (I) comprises SEQ ID NO: 23 and the fusion protein of Formula (II) comprises SEQ ID NO: 22.
31. A construct having a structure depicted in Figure 2, wherein A is an antibody or antibody fragment, B is the polypeptide of claim 1 , C is an immunoglobulin light chain constant region, D is an immunoglobulin heavy chain constant region, E is an Fc region or portion thereof, and straight lines are optional linker sequences; and wherein C and D are optionally joined via disulfide bonds, and the two Fc regions are optionally joined via disulfide bonds.
32. A composition comprising the construct of any one of claims 25-31 and a carrier.
33. A conjugate comprising (a) the polypeptide of claim 1, the fusion protein of any one of claims 3-18, or the construct of any one of claims 25-31 and (b) a cytotoxic agent.
34. The conjugate of claim 33, wherein the cytotoxic agent is a toxin.
35. A composition comprising the conjugate of claim 33 or 34 and a carrier.
36. A method of prophylactically or therapeutically inhibiting a viral infection in a cell or host comprising administering to the cell or host (i) the polypeptide of claim 1 , (ii) the fusion protein of any one of claims 3-18, (iii) the nucleic acid of claim 20 or 21, (iv) the vector of claim 22, (v) the cell of claim 23, (vi) the construct of any one of claims 25-31 , (vii) the conjugate of claim 33 or 34, or (viii) a composition thereof, such that the viral infection is inhibited.
37. The method of claim 36, wherein the viral infection is an HIV infection.
38. The method of claim 37, wherein the HIV infection is an HIV-1 infection.
39. A method of eradicating viral-infected cells in a subject comprising administering the conjugate of claim 33 or 34 or the composition of claim 35 to the subject, thereby eradicating the viral-infected cells in the subject.
40. The method of claim 39, wherein the viral-infected cells are HIV-infected cells.
41. The method of claim 40, wherein the HIV-infected cells are HIV-1 infected cells.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/777,245 US20160039904A1 (en) | 2013-03-15 | 2014-03-12 | Stabilized single human cd4 domains and fusion proteins |
CN201480026873.8A CN105209057B (en) | 2013-03-15 | 2014-03-12 | Stable human single CD4 domain and fusion protein |
EP14717291.0A EP2968453B1 (en) | 2013-03-15 | 2014-03-12 | Stabilized single human cd4 domains and fusion proteins |
US15/784,988 US10647754B2 (en) | 2013-03-15 | 2017-10-16 | Stabilized single human CD4 domains and fusion proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791885P | 2013-03-15 | 2013-03-15 | |
US61/791,885 | 2013-03-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/777,245 A-371-Of-International US20160039904A1 (en) | 2013-03-15 | 2014-03-12 | Stabilized single human cd4 domains and fusion proteins |
US15/784,988 Division US10647754B2 (en) | 2013-03-15 | 2017-10-16 | Stabilized single human CD4 domains and fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014150748A2 true WO2014150748A2 (en) | 2014-09-25 |
WO2014150748A3 WO2014150748A3 (en) | 2014-11-13 |
Family
ID=50483521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/024120 WO2014150748A2 (en) | 2013-03-15 | 2014-03-12 | Stabilized single human cd4 domains and fusion proteins |
Country Status (4)
Country | Link |
---|---|
US (2) | US20160039904A1 (en) |
EP (1) | EP2968453B1 (en) |
CN (1) | CN105209057B (en) |
WO (1) | WO2014150748A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016153572A1 (en) * | 2015-03-25 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
WO2018039626A1 (en) * | 2016-08-25 | 2018-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human single domain antibodies targeting cd16a to mediate adcc |
US10287340B2 (en) | 2008-01-07 | 2019-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-HIV domain antibodies and method of making and using same |
US10894819B2 (en) | 2017-12-20 | 2021-01-19 | Lentigen Technology, Inc. | Compositions and methods for treating HIV/AIDS with immunotherapy |
JP2021518171A (en) * | 2018-03-21 | 2021-08-02 | ザ スクリプス リサーチ インスティテュート | CD4 Mutane and how to use it |
WO2022046644A1 (en) | 2020-08-25 | 2022-03-03 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting hiv and methods of use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015876A (en) | 1995-04-27 | 2000-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | Method of using cyanovirins |
US7491798B2 (en) | 2002-05-16 | 2009-02-17 | The United States Of America As Represented By The Department Of Health And Human Services | Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins |
US20090092557A1 (en) | 2004-06-01 | 2009-04-09 | Government Of The United States Of America Department Of Health And Human Services | Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use |
WO2009089295A2 (en) | 2008-01-07 | 2009-07-16 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-hiv domain antibodies and method of making and using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL87902A0 (en) | 1987-10-08 | 1989-03-31 | Dana Farber Cancer Inst Inc | Soluble human cd4 fragments and applications thereof |
US7501494B2 (en) * | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
US8911728B2 (en) | 2010-05-21 | 2014-12-16 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins |
WO2012113348A1 (en) * | 2011-02-25 | 2012-08-30 | 厦门大学 | Anti-cd4 protein monoclonal antibody, active fragments and uses thereof |
EP3274368A1 (en) | 2015-03-25 | 2018-01-31 | THE UNITED STATES OF AMERICA, represented by the S | Bispecific multivalent fusion proteins |
-
2014
- 2014-03-12 CN CN201480026873.8A patent/CN105209057B/en active Active
- 2014-03-12 US US14/777,245 patent/US20160039904A1/en not_active Abandoned
- 2014-03-12 EP EP14717291.0A patent/EP2968453B1/en active Active
- 2014-03-12 WO PCT/US2014/024120 patent/WO2014150748A2/en active Application Filing
-
2017
- 2017-10-16 US US15/784,988 patent/US10647754B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015876A (en) | 1995-04-27 | 2000-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | Method of using cyanovirins |
US7491798B2 (en) | 2002-05-16 | 2009-02-17 | The United States Of America As Represented By The Department Of Health And Human Services | Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins |
US20090092557A1 (en) | 2004-06-01 | 2009-04-09 | Government Of The United States Of America Department Of Health And Human Services | Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use |
WO2009089295A2 (en) | 2008-01-07 | 2009-07-16 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-hiv domain antibodies and method of making and using same |
Non-Patent Citations (33)
Title |
---|
A.R. GENNARO: "Remington: The Science and Practice ofPharmacy", 1995, MACK PUBLISHING COMPANY |
ANDREU ET AL., J. INFECT. DIS., vol. 171, no. 5, 1995, pages 1237 - 43 |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1994, GREENE PUBLISHING ASSOCIATES AND JOHN WILEY & SONS |
BROWN ET AL., VIROLOGY, vol. 375, 2008, pages 529 - 538 |
CHAN ET AL.: "Fmoc Solid Phase Peptide Synthesis", 2005, OXFORD UNIVERSITY PRESS |
CHEN ET AL., J VIROL., vol. 85, 2011, pages 9395 - 9405 |
CHEN ET AL., J. VIROL., vol. 85, 2011, pages 9395 - 9405 |
CHEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, 2008, pages 17121 - 17126 |
DALGLEISH ET AL., NATURE, vol. 312, 1984, pages 763 - 767 |
DAVIS ET AL., BASIC METHODS IN MOLECULAR BIOLOGY, 1986 |
DEEN ET AL., NATURE, vol. 331, 1988, pages 82 - 84 |
FENG ET AL., ARTHRITIS RES. THER., vol. 13, 2011, pages R59 |
FLINT ET AL.: "Principles of Virology: Molecular Biology, Pathogenesis, and Control", 2000, ASM PRESS |
GERMAIN, CURR. BIOL., vol. 7, 1997, pages R640 - R644 |
H.E. KAUFFMAN, A. SHER, AND R. AHMED: "Immunology of Infectious Disease", 2002, ASM PRESS, article SILVESTRI ET AL.: "Immune Intervention in AIDS" |
KWONG ET AL., NATURE, vol. 393, 1998, pages 648 - 659 |
LIAO ET AL., VIROLOGY, vol. 353, 2006, pages 268 - 282 |
MOEBIUS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 8259 - 8263 |
NEUMANN ET AL., EMBO J., vol. 1, 1982, pages 841 |
REID, R.: "Peptide and Protein Drug Analysis", 2000, MARCEL DEKKER, INC. |
ROBEN ET AL., J VIROL., vol. 68, 1994, pages 4821 - 4828 |
RYU ET AL., NATURE, vol. 348, 1990, pages 419 - 429 |
SAKIHAMA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 6444 - 6448 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR PRESS |
SHANG ET AL., J. BIOL. CHEM., vol. 286, 2011, pages 14531 - 14541 |
SHARMA ET AL., BIOCHEMISTRY, vol. 44, 2005, pages 16192 - 16202 |
TRAUNECKER ET AL., NATURE, vol. 331, 1988, pages 84 - 86 |
WANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 98, 2001, pages 10799 - 10804 |
WESTWOOD ET AL: "Epitope Mapping", 2000, OXFORD UNIVERSITY PRESS |
WILSON ET AL., CELL, vol. 37, 1984, pages 767 |
WU ET AL., NATURE, vol. 387, 1997, pages 527 - 530 |
YAO ET AL., J. BIOL. CHEM., vol. 287, 2012, pages 6788 - 6796 |
ZHU ET AL., J INFECT. DIS., vol. 197, 2008, pages 846 - 853 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10287340B2 (en) | 2008-01-07 | 2019-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-HIV domain antibodies and method of making and using same |
WO2016153572A1 (en) * | 2015-03-25 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
US10472412B2 (en) * | 2015-03-25 | 2019-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
EP3590961A1 (en) | 2015-03-25 | 2020-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
WO2018039626A1 (en) * | 2016-08-25 | 2018-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human single domain antibodies targeting cd16a to mediate adcc |
US10894819B2 (en) | 2017-12-20 | 2021-01-19 | Lentigen Technology, Inc. | Compositions and methods for treating HIV/AIDS with immunotherapy |
US20210206839A1 (en) * | 2017-12-20 | 2021-07-08 | Lentigen Technology, Inc. | Compositions and methods for treating hiv/aids with immunotherapy |
JP2021518171A (en) * | 2018-03-21 | 2021-08-02 | ザ スクリプス リサーチ インスティテュート | CD4 Mutane and how to use it |
EP3768293A4 (en) * | 2018-03-21 | 2022-07-06 | The Scripps Research Institute | Cd4 muteins and methods of using the same |
WO2022046644A1 (en) | 2020-08-25 | 2022-03-03 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting hiv and methods of use |
Also Published As
Publication number | Publication date |
---|---|
US10647754B2 (en) | 2020-05-12 |
US20160039904A1 (en) | 2016-02-11 |
US20180086812A1 (en) | 2018-03-29 |
CN105209057A (en) | 2015-12-30 |
EP2968453A2 (en) | 2016-01-20 |
EP2968453B1 (en) | 2019-12-04 |
CN105209057B (en) | 2020-03-27 |
WO2014150748A3 (en) | 2014-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10647754B2 (en) | Stabilized single human CD4 domains and fusion proteins | |
US8911728B2 (en) | High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins | |
US10421802B2 (en) | Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides | |
US7939083B2 (en) | Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain | |
US10472412B2 (en) | Bispecific multivalent fusion proteins | |
US20230257726A1 (en) | Ace2 compositions and methods | |
US8741310B2 (en) | Fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies | |
AU2005302416A1 (en) | Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies | |
JP2023055875A (en) | Polypeptides targeting hiv fusion | |
JP2020501506A (en) | Anti-NKp46 antibody and therapeutic use thereof | |
CA3173064A1 (en) | Soluble ace2 and fusion protein, and applications thereof | |
WO2018039626A1 (en) | Human single domain antibodies targeting cd16a to mediate adcc | |
WO2000055207A1 (en) | A novel chimeric protein for prevention and treatment of hiv infection | |
CN116059348A (en) | Use of NKG 2D-based cell adaptor molecules for the removal of senescent cells | |
WO2006028634A2 (en) | Site specific pegylation of broadly-neutralizing antibodies against hepatitis c virus and their use in the treatment of chronic hcv infections | |
WO2022079606A1 (en) | Sars cov-2 neutralizing antibodies | |
WO2024023340A1 (en) | Lysosomal degradation | |
WO2023043880A1 (en) | Hiv-binding peptides and medical use thereof | |
EP2392351A1 (en) | Hiv replication inhibitor, and use thereof | |
WO2023105281A1 (en) | Soluble tigit recombinant proteins | |
CN117279947A (en) | Antigen binding molecules targeting CD20 and CD22 for use in proliferative diseases | |
US20070003565A1 (en) | Use of hab18g/cd147 molecule as target for antiviral antagonists and thus obtained antiviral antagonist | |
WO2006026097A2 (en) | Pegylation of antibodies against hiv | |
Couto | Synthetic antibodies targeting HIV-1 infectivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2014717291 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14717291 Country of ref document: EP Kind code of ref document: A2 |